<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacy (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacy (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">3194</journal-id><journal-id journal-id-type="pmc-domain">pharmacy</journal-id><journal-id journal-id-type="publisher-id">pharmacy</journal-id><journal-title-group><journal-title>Pharmacy</journal-title></journal-title-group><issn pub-type="epub">2226-4787</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10302283</article-id><article-id pub-id-type="pmcid-ver">PMC10302283.1</article-id><article-id pub-id-type="pmcaid">10302283</article-id><article-id pub-id-type="pmcaiid">10302283</article-id><article-id pub-id-type="pmid">37368424</article-id><article-id pub-id-type="doi">10.3390/pharmacy11030099</article-id><article-id pub-id-type="publisher-id">pharmacy-11-00099</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Organizational Readiness to Implement Community Pharmacy-Based Opioid Counseling and Naloxone Services: A Scoping Review of Current Practice Models and Opportunities</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8348-0895</contrib-id><name name-style="western"><surname>Hohmann</surname><given-names initials="L">Lindsey</given-names></name><xref rid="af1-pharmacy-11-00099" ref-type="aff">1</xref><xref rid="c1-pharmacy-11-00099" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harris</surname><given-names initials="K">Klaudia</given-names></name><xref rid="af1-pharmacy-11-00099" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="Y">Yi</given-names></name><xref rid="af2-pharmacy-11-00099" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marlowe</surname><given-names initials="K">Karen</given-names></name><xref rid="af1-pharmacy-11-00099" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Phillippe</surname><given-names initials="H">Haley</given-names></name><xref rid="af1-pharmacy-11-00099" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Correia</surname><given-names initials="C">Chris</given-names></name><xref rid="af3-pharmacy-11-00099" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fox</surname><given-names initials="B">Brent</given-names></name><xref rid="af2-pharmacy-11-00099" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Matheson</surname><given-names initials="C">Catriona</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmacy-11-00099"><label>1</label>Department of Pharmacy Practice, Harrison College of Pharmacy, Auburn University, 1330 Walker Building, Auburn, AL 36849, USA; <email>kkh0019@auburn.edu</email> (K.H.); <email>marlokf@auburn.edu</email> (K.M.); <email>phillh1@auburn.edu</email> (H.P.)</aff><aff id="af2-pharmacy-11-00099"><label>2</label>Department of Health Outcomes Research and Policy, Harrison College of Pharmacy, Auburn University, 4306 Walker Building, Auburn, AL 36849, USA; <email>yzz0167@auburn.edu</email> (Y.Z.); <email>foxbren@auburn.edu</email> (B.F.)</aff><aff id="af3-pharmacy-11-00099"><label>3</label>Department of Psychological Sciences, College of Liberal Arts, Auburn University, 221 Cary Hall, Auburn, AL 36849, USA; <email>correcj@auburn.edu</email></aff><author-notes><corresp id="c1-pharmacy-11-00099"><label>*</label>Correspondence: <email>lah0036@auburn.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2023</year></pub-date><volume>11</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">436388</issue-id><elocation-id>99</elocation-id><history><date date-type="received"><day>06</day><month>5</month><year>2023</year></date><date date-type="rev-recd"><day>07</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>08</day><month>6</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>06</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>29</day><month>06</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-06-29 13:25:09.673"><day>29</day><month>06</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmacy-11-00099.pdf"/><abstract><p>The purpose of this study was to explore existing practice models and opportunities surrounding community pharmacist-delivered opioid counseling and naloxone (OCN) services in the U.S., with the goal of enhancing organizational readiness and improving patient access. A scoping literature review was conducted. English-language articles published in peer-reviewed journals from January 2012&#8211;July 2022 were sought via PubMed, CINAHL, IPA, and Google Scholar using permutations of terms such as &#8220;pharmacist/pharmacy&#8221;, &#8220;opioid/opiate&#8221;, &#8220;naloxone&#8221;, &#8220;counseling&#8221;, and &#8220;implement/implementation&#8221;. Original articles reporting the resources/inputs (personnel; pharmacist full-time equivalents; facilities and expenses; in-house versus outsourced personnel), implementation processes (legal source of pharmacist authority; patient identification strategies; intervention procedures; workflow strategies; business operations), and programmatic outcomes (uptake and delivery; interventions made; economic impact; patient or provider satisfaction) of pharmacist-delivered OCN services in community (retail) settings were retained. Twelve articles describing ten unique studies were included. The studies primarily used quasi-experimental designs and were published from 2017 to 2021. The articles described seven broad program elements/themes: interprofessional collaboration (<italic toggle="yes">n</italic> = 2); patient education format including one-on-one patient education (<italic toggle="yes">n</italic> = 12) and group education sessions (<italic toggle="yes">n</italic> = 1); non-pharmacist provider education (<italic toggle="yes">n</italic> = 2); pharmacy staff education (<italic toggle="yes">n</italic> = 8); opioid misuse screening tools (<italic toggle="yes">n</italic> = 7); naloxone recommendation/dispensing (<italic toggle="yes">n</italic> = 12); and opioid therapy and pain management (<italic toggle="yes">n</italic> = 1). Pharmacists screened/counseled 11&#8211;2716 patients and provided 11&#8211;430 doses of naloxone. Limited implementation costs, patient/provider satisfaction, or economic impact measures were reported. This review may serve as a guide for community pharmacists in implementing OCN services in their own practices. Future studies should clarify OCN program implementation costs, patient/provider satisfaction, and the economic impact.</p></abstract><kwd-group><kwd>opioid counseling</kwd><kwd>naloxone service</kwd><kwd>community pharmacy</kwd><kwd>implementation</kwd></kwd-group><funding-group><award-group><funding-source>Auburn University Intramural Grants Program (IGP) Early Career Development</funding-source><award-id>IGP 200917</award-id></award-group><funding-statement>This study was funded by the Auburn University Intramural Grants Program (IGP) Early Career Development Grant (grant no. IGP 200917).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmacy-11-00099"><title>1. Introduction</title><p>Opioid misuse is a major public health issue in the United States. Opioids are a class of medications that include drugs such as oxycodone, hydrocodone, codeine, and morphine [<xref rid="B1-pharmacy-11-00099" ref-type="bibr">1</xref>]. Of the 92,000 drug overdose deaths recorded in 2020 in the US, 75% of those involved an opioid [<xref rid="B2-pharmacy-11-00099" ref-type="bibr">2</xref>]. Furthermore, it is estimated that 44 people die every day from overdoses involving prescription opioids [<xref rid="B3-pharmacy-11-00099" ref-type="bibr">3</xref>]. In recent years, the Centers for Disease Control and Prevention (CDC) noted that drug overdose deaths are rising in both rural and urban areas [<xref rid="B4-pharmacy-11-00099" ref-type="bibr">4</xref>], posing a significant economic burden, with the U.S economic cost of opioid use disorder (OUD) and fatal opioid overdose during 2017 totaling USD 1021 billion [<xref rid="B5-pharmacy-11-00099" ref-type="bibr">5</xref>]. Thus, it is increasingly important that healthcare providers are ready to combat this epidemic.</p><p>Community pharmacists are well placed to take the lead in combatting the opioid epidemic by providing access to naloxone, the opioid overdose antidote [<xref rid="B6-pharmacy-11-00099" ref-type="bibr">6</xref>]. All U.S. states have enacted naloxone access laws, allowing pharmacists to provide naloxone without a physician visit via statewide standing orders, protocols, or pharmacist prescriptive authority, depending on the state [<xref rid="B7-pharmacy-11-00099" ref-type="bibr">7</xref>,<xref rid="B8-pharmacy-11-00099" ref-type="bibr">8</xref>]. Community pharmacy-based opioid counseling and naloxone services (OCN) may include education on opioid dosing and side effects, risks of overdose, signs and symptoms of overdose, overdose management, the identification of opioid compounds, and naloxone recommendations, dispensing, and counseling. Pharmacy-based OCN services have been shown to increase patient awareness of overdose risk, increase patient access to naloxone, and decrease opioid overdose mortality [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B11-pharmacy-11-00099" ref-type="bibr">11</xref>,<xref rid="B12-pharmacy-11-00099" ref-type="bibr">12</xref>,<xref rid="B13-pharmacy-11-00099" ref-type="bibr">13</xref>,<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>]. Despite this, naloxone dispensing is not at capacity, with only 1 naloxone prescription dispensed out of every 69 high-dose opioid prescriptions in 2018 [<xref rid="B12-pharmacy-11-00099" ref-type="bibr">12</xref>]. With the U.S. Food and Drug Administration&#8217;s approval of the over-the-counter (OTC) status of the 4 mg naloxone nasal spray (Narcan<sup>&#174;</sup>) on 29 March 2023 [<xref rid="B15-pharmacy-11-00099" ref-type="bibr">15</xref>], methods for enhancing community pharmacy-based OCN services and bringing them up to capacity are even more critical.</p><p>However, little is known about pharmacists&#8217; organizational readiness to implement OCN services. Previous research has focused on improving pharmacist knowledge and training related to naloxone [<xref rid="B16-pharmacy-11-00099" ref-type="bibr">16</xref>], pain management [<xref rid="B17-pharmacy-11-00099" ref-type="bibr">17</xref>], the treatment of opioid use disorder [<xref rid="B18-pharmacy-11-00099" ref-type="bibr">18</xref>], and enhancing naloxone dispensing [<xref rid="B16-pharmacy-11-00099" ref-type="bibr">16</xref>]. Limited research has explored the structures and processes underlying community pharmacy-based naloxone services implementation, including the service workflows currently being utilized, the resources used, and the cost of implementation [<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>]. Understanding these factors is the first step in identifying best practices and actionable gaps in practice that can be leveraged to enhance OCN services. Furthermore, given the recent approval of Narcan&#8217;s<sup>&#174;</sup> OTC status [<xref rid="B15-pharmacy-11-00099" ref-type="bibr">15</xref>], leveraging the best practices and identifying actionable gaps is more urgent than ever in order to prepare pharmacists for potential increases in naloxone inquiries from their patients. Therefore, the purpose of this study was to explore the existing practice models and practice opportunities surrounding community pharmacist-delivered opioid counseling and naloxone services in the United States, with the goal of enhancing organizational readiness and improving patient access.</p></sec><sec id="sec2-pharmacy-11-00099"><title>2. Review Process</title><p>In order to broadly explore current community pharmacy-based OCN practice models and opportunities for service enhancement, a scoping review of the literature was conducted. The review methodology, including data extraction and data synthesis, was informed by scoping review recommendations published by Arksey and O&#8217;Malley [<xref rid="B20-pharmacy-11-00099" ref-type="bibr">20</xref>] and Levac and colleagues [<xref rid="B21-pharmacy-11-00099" ref-type="bibr">21</xref>].</p><sec id="sec2dot1-pharmacy-11-00099"><title>2.1. Data Sources and Search Terms</title><p>A broad search of the literature was conducted using the PubMed, CINAHL, IPA, and Google Scholar online databases in July 2022. A priori search terms were chosen in order to best characterize the development, implementation, and current operations of community pharmacy-based opioid counseling and naloxone (OCN) services. Community pharmacies were defined as retail pharmacies that serve the public. In order to encompass a wide range of service/program models, OCN services were loosely defined as any naloxone dispensing, naloxone recommendations, naloxone education, or illicit/prescription opioid counseling provided by pharmacy personnel to people who use opioids, their caregivers, or other healthcare providers. Searches included permutations of terms such as: &#8220;pharmacist/pharmacy&#8221;, &#8220;opioid/opiate&#8221;, &#8220;naloxone&#8221;, &#8220;counseling&#8221;, &#8220;program&#8221;, &#8220;resource&#8221;, &#8220;process&#8221;, &#8220;intervention&#8221;, &#8220;financial&#8221;, &#8220;satisfaction&#8221;, &#8220;develop/development&#8221;, and &#8220;implement/implementation&#8221; (<xref rid="pharmacy-11-00099-t001" ref-type="table">Table 1</xref>) [<xref rid="B22-pharmacy-11-00099" ref-type="bibr">22</xref>]. Searches were limited to English-language articles published between January 2012 (when pharmacy naloxone access laws began in the U.S.) and July 2022. Reference lists of published studies were also manually searched to find additional articles that may have been missed in database searches.</p></sec><sec id="sec2dot2-pharmacy-11-00099"><title>2.2. Study Selection, Outcome Measures, and Data Extraction</title><p>Studies were eligible for inclusion in the scoping review if they used an experimental, quasi-experimental, or observational study design, described a community pharmacy-based OCN program/service, and reported at least one outcome measure of interest with extractable data. Outcome measures and categories of interest included: (1) resources and inputs involved in community pharmacy-based OCN program development (personnel; pharmacist full-time equivalents; facilities and expenses; in-house versus outsourced personnel); (2) program/service implementation processes (legal source of pharmacist authority; patient identification strategies; intervention procedures; workflow strategies; business operations); and (3) programmatic outcomes (uptake and delivery; interventions made; economic impact; patient or provider satisfaction). Outcome measures were broadly guided by the Donabedian Model for Quality of Care, which postulates that an organization&#8217;s structures (resources and inputs) influence its processes (implementation processes), which in turn influence outcomes (programmatic outcomes) [<xref rid="B23-pharmacy-11-00099" ref-type="bibr">23</xref>,<xref rid="B24-pharmacy-11-00099" ref-type="bibr">24</xref>]. Categories within resources/inputs (e.g., personnel), implementation processes (e.g., patient identification strategies), and programmatic outcomes (e.g., economic impact) measures were further informed by previous work by Hohmann et al. [<xref rid="B22-pharmacy-11-00099" ref-type="bibr">22</xref>] and the ECHO (economic, clinical, and humanistic outcomes) Model [<xref rid="B25-pharmacy-11-00099" ref-type="bibr">25</xref>]. Studies describing programs that were not pharmacist-delivered (e.g., delivered by a nurse or other healthcare professional), conducted outside of the United States, or conducted in a setting other than a community pharmacy were excluded from the review.</p><p>Searches were conducted by two investigators (L.H., K.H.), beginning with the title and abstract review, followed by a full text review and hand-searching of reference lists. The final articles included in the review were agreed upon by the research team (B.F., H.P., K.M., C.C., Y.Z.), which included a diverse array of content experts, as recommended by Arksey, O&#8217;Malley, Levac, and colleagues [<xref rid="B20-pharmacy-11-00099" ref-type="bibr">20</xref>,<xref rid="B21-pharmacy-11-00099" ref-type="bibr">21</xref>], with discrepancies resolved via discourse and consensus. Data were extracted by two investigators (L.H., K.H.) using a standardized template, including the study design, setting, study period, study population, and outcomes variables. EndNote version X9 (Clarivate&#8482;, Philadelphia, PA, USA) citation management software was used as a data organization tool and to assist with the removal of duplicate articles.</p></sec><sec id="sec2dot3-pharmacy-11-00099"><title>2.3. Data Synthesis</title><p>The final retained articles were assessed using a qualitative narrative synthesis technique to identify broad OCN program elements/themes and summarize outcome measures of interest. Specifically, following a precedent set by Nielsen and Van Hout [<xref rid="B26-pharmacy-11-00099" ref-type="bibr">26</xref>], a qualitative content analysis process was used to inductively identify core OCN program elements across studies. Subsequent to this initial round of content analysis, core program elements were revised to create final program themes and sub-themes. Additionally, resources/inputs, implementation processes, and programmatic outcomes data were deductively grouped into each of the aforementioned pre-determined categories informed by Hohmann et al. [<xref rid="B22-pharmacy-11-00099" ref-type="bibr">22</xref>] and the ECHO model [<xref rid="B25-pharmacy-11-00099" ref-type="bibr">25</xref>] (e.g., workflow strategies; see <xref rid="sec2dot2-pharmacy-11-00099" ref-type="sec">Section 2.2</xref>) and then inductively organized into meaningful sub-categories in order to provide a broad picture of the &#8220;building blocks&#8221; involved in OCN service development and implementation. Data synthesis was performed by a single investigator (L.H.) in consultation with the research team, and the final results were agreed upon by all members. </p></sec></sec><sec sec-type="results" id="sec3-pharmacy-11-00099"><title>3. Results</title><p>A total of 271 database hits were obtained, and 269 articles were assessed for inclusion criteria via the title and abstract review after the removal of duplicates (<xref rid="pharmacy-11-00099-f001" ref-type="fig">Figure 1</xref>). Forty-four full-text articles were screened for eligibility, with an additional four articles obtained by hand-searching reference lists. Twelve articles describing ten unique studies representing current community pharmacist-delivered opioid counseling and naloxone (OCN) practices were retained in the final review [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>].</p><sec id="sec3dot1-pharmacy-11-00099"><title>3.1. Study Characteristics</title><p>Studies meeting the inclusion criteria for the review were published between 2017 and 2021 and primarily used quasi-experimental (<italic toggle="yes">n</italic> = 8) and observational (<italic toggle="yes">n</italic> = 3) study designs, with a single experimental design (<xref rid="pharmacy-11-00099-t002" ref-type="table">Table 2</xref>). One-group (single-arm) studies were predominant (<italic toggle="yes">n</italic> = 9), including pretest&#8211;posttest (<italic toggle="yes">n</italic> = 5) [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>], posttest (<italic toggle="yes">n</italic> = 1) [<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>], and retrospective cohort (<italic toggle="yes">n</italic> = 3) [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>] designs. Two-group study designs included non-randomized controlled trials (<italic toggle="yes">n</italic> = 2) [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>] and a single randomized controlled trial (<italic toggle="yes">n</italic> = 1) [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>]. The largest number of articles (<italic toggle="yes">n</italic> = 4) described studies conducted in North Dakota, with others taking place in Pennsylvania (<italic toggle="yes">n</italic> = 2), Arkansas (<italic toggle="yes">n</italic> = 1), California (<italic toggle="yes">n</italic> = 1), North Carolina (<italic toggle="yes">n</italic> = 1), Ohio (<italic toggle="yes">n</italic> = 1), Washington (<italic toggle="yes">n</italic> = 1), and West Virginia (<italic toggle="yes">n</italic> = 1). The patient population served by each community pharmacy-based OCN program included all patients receiving opioid therapy (<italic toggle="yes">n</italic> = 6), patients receiving opioid therapy and at a high risk of overdose (<italic toggle="yes">n</italic> = 4), potential bystanders to an overdose situation (<italic toggle="yes">n</italic> = 1), and those receiving buprenorphine-containing products for the treatment of opioid use disorder (OUD) (<italic toggle="yes">n</italic> = 1).</p></sec><sec id="sec3dot2-pharmacy-11-00099"><title>3.2. Program Themes</title><p>The articles described seven broad program elements/themes (<xref rid="pharmacy-11-00099-t003" ref-type="table">Table 3</xref>): (1) interprofessional collaboration (<italic toggle="yes">n</italic> = 2); (2) patient education format including two sub-themes of one-on-one patient education (<italic toggle="yes">n</italic> = 12) and group education sessions (<italic toggle="yes">n</italic> = 1); (3) non-pharmacist provider education (<italic toggle="yes">n</italic> = 2); (4) pharmacy staff education (<italic toggle="yes">n</italic> = 8); (5) opioid misuse screening tools (<italic toggle="yes">n</italic> = 7); (6) naloxone recommendation/dispensing (<italic toggle="yes">n</italic> = 12); and (7) opioid therapy and pain management (<italic toggle="yes">n</italic> = 1).</p><sec id="sec3dot2dot1-pharmacy-11-00099"><title>3.2.1. Interprofessional Collaboration</title><p>Two articles described community pharmacy-based OCN services incorporating elements of interprofessional collaboration. Specifically, Akers and colleagues [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>] partnered with the Seattle-King County Public Health Department to create a collaborative drug therapy agreement (CDTA) for naloxone and to identify other organizations providing naloxone in their local area. They also provided ready-made naloxone prescription templates and order sets to local prescribers to engage them in the service. Furthermore, Manzur and colleagues [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>] described a collaborative OCN service between a community pharmacy and a nearby rheumatology clinic within an academic medical center, whereby clinic patients prescribed opioids for chronic pain and at a perceived high risk of overdose according to Centers for Disease Control and Prevention (CDC) guidelines [<xref rid="B35-pharmacy-11-00099" ref-type="bibr">35</xref>] were referred to the pharmacy for opioid medication counseling, naloxone counseling, and the provision of naloxone. Pharmacist recommendations regarding therapy were then relayed to the prescriber prior to the patient&#8217;s next clinic appointment.</p></sec><sec id="sec3dot2dot2-pharmacy-11-00099"><title>3.2.2. Patient Education Format: One-on-One Patient Education versus Group Education Sessions</title><p>The patient education format was divided into two sub-themes describing distinct service models: one-on-one education sessions and group education sessions. All articles [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>] described a one-on-one (individual) patient education component of their OCN service, while only one article (Akers et al.) [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>] discussed the provision of group education sessions. Notably, individual education sessions primarily focused on counseling regarding naloxone administration and how to recognize and manage an opioid overdose. Materials such as checklists, pamphlets, and posters used in these individual counseling sessions were adapted from the Substance Abuse and Mental Health Services Administration (SAMHSA) toolkit [<xref rid="B36-pharmacy-11-00099" ref-type="bibr">36</xref>] and templates available from Prescribe to Prevent [<xref rid="B37-pharmacy-11-00099" ref-type="bibr">37</xref>] and the Maximizing OpiOid Safety with Naloxone (MOON) study [<xref rid="B38-pharmacy-11-00099" ref-type="bibr">38</xref>]. Some studies mentioned the incorporation of video training demonstrating naloxone administration techniques into individual sessions; for example, Akers and colleagues cited publicly available You Tube videos [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>]. In terms of group education sessions, Akers and colleagues [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>] described group sessions provided to the community that focused on several elements surrounding opioid overdoses, including: (1) how to manage an overdose situation; (2) how to train others; (3) statistics; and (4) dispelling myths.</p></sec><sec id="sec3dot2dot3-pharmacy-11-00099"><title>3.2.3. Non-Pharmacist Provider Education</title><p>Two studies reported multidisciplinary healthcare provider education (education of providers outside of the pharmacy) as part of their OCN service [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>]. For example, Akers and colleagues [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>] discussed the implementation of opioid overdose and naloxone education for local physicians with practice sites near the community pharmacy in Washington State. In addition, providers were given ready-to-use naloxone prescription templates from Prescribe to Prevent [<xref rid="B37-pharmacy-11-00099" ref-type="bibr">37</xref>] and directed to the Interagency Guideline of Prescribing Opioids for pain from the Washington State Agency Medical Directors Group [<xref rid="B39-pharmacy-11-00099" ref-type="bibr">39</xref>], which outlined how to identify patients with risk factors for opioid overdoses. Similarly, Manzur and colleagues [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>] mentioned providing education to prescribers located at a nearby rheumatology clinic, including information regarding naloxone administration, pain management strategies (pharmacologic, non-pharmacologic, lifestyle), interactions, and side effects.</p></sec><sec id="sec3dot2dot4-pharmacy-11-00099"><title>3.2.4. Pharmacy Staff Education</title><p>Eight articles described training pharmacy personnel regarding opioid overdose management and naloxone as part of their OCN service [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>]. Of these, two articles discussed using national, publicly available sources to adapt and inform their training materials. Specifically, Wilkerson and colleagues [<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>] utilized training videos from Prescribe to Prevent [<xref rid="B39-pharmacy-11-00099" ref-type="bibr">39</xref>], and Akers and colleagues [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>] used the SAMHSA toolkit [<xref rid="B36-pharmacy-11-00099" ref-type="bibr">36</xref>] to inform their training checklist. Five articles utilized statewide experts or sources to develop their training, while two used local and intraorganizational sources. For example, in terms of statewide experts and sources, Skoy and colleagues [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>] and Strand and colleagues [<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>] developed their pharmacist training program in collaboration with faculty from North Dakota State University and state public health officials, and Santa and colleagues [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>] utilized an SBIRT (screening, brief intervention, and referral to treatment) training previously developed by the University of Pittsburgh. At the local and intraorganizational level, Sexton and colleagues [<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>] utilized training delivered by the pharmacy&#8217;s clinical pharmacist and resident, and Wilkerson and colleagues [<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>] used a training video developed by the pharmacy&#8217;s corporate team in addition to the aforementioned nationally sourced training. Furthermore, the largest number of articles described the provision of a hybrid (online and in-person) training format (<italic toggle="yes">n</italic> = 5) [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>], followed by online only (<italic toggle="yes">n</italic> = 2) [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>] and in-person only (<italic toggle="yes">n</italic> = 1) [<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>]. Three articles mentioned using video media to demonstrate opioid overdose management and naloxone administration [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>], and one mentioned the use of a simulation [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>]. Only Skoy and colleagues [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>] and Strand and colleagues [<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>] reported the development of training specific for pharmacy technicians. The length of pharmacist training was infrequently reported, but in those articles in which it was discussed, training ranged from 3 h [<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>] to a full day [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>], with continuing education credit offered.</p></sec><sec id="sec3dot2dot5-pharmacy-11-00099"><title>3.2.5. Opioid Misuse Screening Tools</title><p>Seven articles describe the usage of an opioid misuse screening tool when implementing community pharmacy-based OCN services [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>]. Cochran and colleagues [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>] screened patients for opioid misuse at the time of service using the Prescription Opioid Misuse Index (POMI) [<xref rid="B40-pharmacy-11-00099" ref-type="bibr">40</xref>], which is explained as a brief six-item questionnaire that asks patients about behaviors related to their current use of opioid pain medication. The POMI is scored from 0 to 6, with scores of 2 or above indicating the potential for opioid misuse [<xref rid="B40-pharmacy-11-00099" ref-type="bibr">40</xref>]. In contrast to a point-of-service screening, Skoy and colleagues [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>] and Strand and colleagues [<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>] used an electronic or hardcopy opioid misuse screener (the Opioid Risk Tool (ORT) [<xref rid="B41-pharmacy-11-00099" ref-type="bibr">41</xref>]) embedded in their patient intake form. Using the ORT, the risk of opioid misuse is scored from 0 to 26, with scores over 8 indicating a high risk and a greater need for naloxone [<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>]. This screening tool was provided to pharmacies in an Opioid Misuse Risk Prevention toolkit as part of the larger ONE Rx pharmacist opioid and naloxone education program in North Dakota [<xref rid="B42-pharmacy-11-00099" ref-type="bibr">42</xref>]. Manzur and colleagues [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>] also used the ORT as part of a comprehensive pain management assessment. Additionally, Santa and colleagues [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>] utilized the SBIRT framework, which provides a guide for action including screening, brief intervention (patient counseling), and referral to treatment [<xref rid="B43-pharmacy-11-00099" ref-type="bibr">43</xref>]; however, although it was mentioned that a formal opioid misuse screening tool was used, no further information regarding the screening tool was provided.</p></sec><sec id="sec3dot2dot6-pharmacy-11-00099"><title>3.2.6. Naloxone Recommendation/Dispensing</title><p>All studies incorporated naloxone recommendations into their pharmacy-based OCN services [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B11-pharmacy-11-00099" ref-type="bibr">11</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>]. The largest number of articles (<italic toggle="yes">n</italic> = 5) [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>] reported using educational brochures, pamphlets, or handouts to guide their naloxone recommendations to patients, while very few mentioned using video presentations (<italic toggle="yes">n</italic> = 1) [<xref rid="B11-pharmacy-11-00099" ref-type="bibr">11</xref>] or naloxone demonstration kits (<italic toggle="yes">n</italic> = 1) [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>]. Neither Cochran and colleagues [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>] nor Manzur and colleagues [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>] reported the use of any patient education materials in guiding their naloxone counseling. Although Santa and colleagues [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>] likewise did not mention the use of patient-facing naloxone education materials, they utilized a workflow outline to evaluate and monitor the pharmacy&#8217;s naloxone dispensing on a weekly basis. Few studies discussed the organization/storage of naloxone educational materials in the pharmacy; those that did (<italic toggle="yes">n</italic> = 3) [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>] mentioned the collation of all printed materials in a binder stored in the pharmacy as well as a dedicated website (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://one-program.org/">https://one-program.org/</uri>, accessed on 8 February 2023) [<xref rid="B44-pharmacy-11-00099" ref-type="bibr">44</xref>] for organizing and archiving naloxone educational materials for future printing. </p></sec><sec id="sec3dot2dot7-pharmacy-11-00099"><title>3.2.7. Opioid Therapy and Pain Management</title><p>Only one study reported conducting comprehensive opioid therapy and pain management in a community pharmacy setting [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>]. Specifically, Manzur and colleagues [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>] assessed patients&#8217; pain management using a numeric pain rating scale and the Pain, Enjoyment, General Activity (PEG) tool [<xref rid="B44-pharmacy-11-00099" ref-type="bibr">44</xref>] as well as associated concomitant disease states including mental health using the Patient Health Questionnaire-9 (PHQ-9) [<xref rid="B45-pharmacy-11-00099" ref-type="bibr">45</xref>]. Pharmacists provided medication recommendations including opioid dose adjustments, the addition of adjuvant therapy, and laboratory tests to the provider who referred the patient to their service. As part of the assessment, they performed opioid risk mitigation strategies including screening for potential misuse using the ORT, PDMP review, opioid and non-opioid pain medication counseling, pain management education (pharmacologic, non-pharmacologic, lifestyle), naloxone education, and naloxone co-prescribing.</p></sec></sec><sec id="sec3dot3-pharmacy-11-00099"><title>3.3. Program Inputs and Resources</title><p>All studies utilized in-house (versus outsourced) pharmacists to perform OCN services; the utilization of pharmacy technicians (<italic toggle="yes">n</italic> = 3) [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>], student pharmacists (<italic toggle="yes">n</italic> = 2) [<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>], and pharmacy residents (<italic toggle="yes">n</italic> = 2) [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>] was also reported in a limited number of studies (<xref rid="pharmacy-11-00099-t004" ref-type="table">Table 4</xref>). Few studies (<italic toggle="yes">n</italic> = 2) reported pharmacist full-time equivalents (FTEs), but among those that did, the mean pharmacist FTEs dedicated to OCN services was 1.5 [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>]. Additionally, a few articles (<italic toggle="yes">n</italic> = 3) described the pharmacy facilities dedicated to OCN services. Specifically, Manzur and colleagues [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>] and Hines and colleagues [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>] reported using a private counseling/exam room to conduct OCN services. Akers and colleagues described a process of &#8220;rooming&#8221; patients prior to counseling, but no further information regarding the facilities was provided [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>]. None of the included articles discussed the expenses incurred in OCN implementation.</p></sec><sec id="sec3dot4-pharmacy-11-00099"><title>3.4. Program Implementation Processes</title><p>The implementation processes utilized in community pharmacy-based OCN were divided into five broad categories (<xref rid="pharmacy-11-00099-t005" ref-type="table">Table 5</xref>): (1) pharmacist authority; (2) patient identification; (3) pharmacist interventions; (4) workflow; and (5) business operations.</p><sec id="sec3dot4dot1-pharmacy-11-00099"><title>3.4.1. Pharmacist Authority</title><p>Eleven articles reported the type of pharmacist authority utilized to provide OCN. The largest number of articles reported the use of a statewide naloxone standing order (<italic toggle="yes">n</italic> = 4) [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>] or pharmacist prescriptive authority (<italic toggle="yes">n</italic> = 4) [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>]. Protocols with local physicians (<italic toggle="yes">n</italic> = 1) [<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>] and collaborative drug therapy agreements (CDTA) (<italic toggle="yes">n</italic> = 1) [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>] were also mentioned. Manzur and colleagues specifically mentioned that they did not use a collaborative practice agreement because their OCN service was strictly consultative [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>].</p></sec><sec id="sec3dot4dot2-pharmacy-11-00099"><title>3.4.2. Patient Identification</title><p>In terms of identifying patient recipients of OCN services, a variety of approaches and communication strategies were described, including general/passive advertisements (posters or flyers displayed in the pharmacy), targeted offers (offering naloxone only to those at increased risk of an opioid overdose based on certain criteria) with or without the use of a screening tool, and universal offers (offering naloxone to all patients prescribed opioids). The majority of articles described using a targeted approach (<italic toggle="yes">n</italic> = 7) [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>], with few using universal (<italic toggle="yes">n</italic> = 2) [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>] or general/passive approaches (<italic toggle="yes">n</italic> = 1) [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>]. Within studies using a targeted approach, some utilized criteria from the CDC Opioid Prescribing Guidelines [<xref rid="B35-pharmacy-11-00099" ref-type="bibr">35</xref>] to determine the risk for an opioid overdose [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>], while others used guidelines set forth by specific screening tools (see the Opioid Misuse Screening Tools sub-section above). Two studies reported using a combination of targeted and general/passive approaches [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>]. Furthermore, two studies discussed the use of technology in patient identification. Specifically, Sexton and colleagues [<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>] and Teeter and colleagues [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>] reported the use of &#8220;clinical flags&#8221; in the pharmacy dispensing software to alert the pharmacist to patients at an increased risk of an opioid overdose or harm from opioids based on pre-determined criteria such as morphine milligram equivalents (MME) and concomitant medications.</p></sec><sec id="sec3dot4dot3-pharmacy-11-00099"><title>3.4.3. Pharmacist Interventions</title><p>The types of services/interventions offered in community pharmacies primarily consisted of opioid education and naloxone dispensing (OEND) (<italic toggle="yes">n</italic> = 9) [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>], with specialized services offered at a few pharmacies, including take-home naloxone (THN) plus an extensive multidisciplinary education program (<italic toggle="yes">n</italic> = 1) [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>], pain medication management (<italic toggle="yes">n</italic> = 1) [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>], and a brief motivational intervention plus medication therapy management (BMI-MTM) (<italic toggle="yes">n</italic> = 1) [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>]. Two studies reported the use of motivational interviewing (MI) concepts in their service/intervention. Specifically, the BMI-MTM intervention performed by Cochran and colleagues incorporated concepts of MI in a pharmacist&#8211;patient consultation [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>], while Santa and colleagues utilized MI during pharmacist&#8211;patient interactions as part of the SBIRT framework guiding their program [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>]. Furthermore, Skoy and colleagues [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>] and Strand and colleagues [<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>] offered additional services as part of their OEND programs, including drug take-back. Although the aforementioned authors [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>], as well as Santa and colleagues [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>], also mentioned referral of patients to community resources for further treatment, specific details regarding the referral process were not reported beyond the provision of a list of local providers.</p></sec><sec id="sec3dot4dot4-pharmacy-11-00099"><title>3.4.4. Workflow</title><p>Community pharmacy-based OCN services/interventions ranged from 5 to 45 min in length [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>], with most offered in-person (<italic toggle="yes">n</italic> = 9) [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>] and on a walk-in basis (<italic toggle="yes">n</italic> = 6) [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>]. Few pharmacies utilized an appointment-based (<italic toggle="yes">n</italic> = 2) [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>] service model, and none used a solely telephonic model. Two articles reported using hybrid service models. Specifically, Cochran and colleagues provided both in-person and telephone-based services [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>], while Akers and colleagues provided services on both a walk-in and appointment basis [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>]. Additionally, nine articles reported using some sort of materials to assist with implementation of their OCN services, including patient intake forms [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>], workflow checklists [<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>], instructions posted at each pharmacy workstation [<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>], and decision-making tools or guides [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>]. In particular, Skoy and colleagues [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>] and Strand and colleagues [<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>] reported using a unique implementation toolkit that included a patient screening form accessed via a mobile device using a QR code, a tablet available at the pharmacy, or paper.</p></sec><sec id="sec3dot4dot5-pharmacy-11-00099"><title>3.4.5. Business Operations</title><p>Five of the twelve articles reported the utilization of marketing materials or campaigns to increase patient demand for OCN services. Specifically, Skoy and colleagues [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>] and Strand and colleagues [<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>] used a comprehensive marketing campaign including television and newspaper interviews, emails from their state board of pharmacy, window clings, posters, brochures, and pharmacist buttons. Wilkerson and colleagues [<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>] used signs advertising the availability of naloxone posted outside the pharmacy, while Teeter and colleagues [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>] utilized posters derived from the MOON study website [<xref rid="B38-pharmacy-11-00099" ref-type="bibr">38</xref>] that were posted inside the pharmacy in the waiting room and at the pick-up counter and rotated weekly. Furthermore, while seven articles reported the use of formalized policies and procedures to guide their OCN services (e.g., clarification of roles, workstation duties, etc.) [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>], only one article described using a formalized process to evaluate OCN service fidelity (how closely the service followed the formal protocol) [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>]. In addition, few articles (<italic toggle="yes">n</italic> = 3) [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>] reported details regarding their service reimbursement model (disregarding cases where reimbursement came from grant funding alone). Specifically, Teeter and colleagues [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>] described naloxone product reimbursement via third-party insurance billing for brand Narcan<sup>&#174;</sup> or generic naloxone vials with a nasal atomizer. Similarly, Hines and colleagues [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>] utilized third-party insurance billing, primarily Medicaid, to reimburse naloxone product costs, although they only stocked and dispensed the Narcan<sup>&#174;</sup> nasal spray due to the greater likelihood of insurance coverage for this formulation. Akers and colleagues [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>] utilized an out-of-pocket reimbursement model incorporating the costs of two naloxone doses, a counseling fee, a nasal atomizer, and a breathing mask.</p></sec></sec><sec id="sec3dot5-pharmacy-11-00099"><title>3.5. Programmatic Outcomes</title><p>Pharmacists screened/counseled between 11 [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>] and 2716 [<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>] patients and provided 11 [<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>] to 430 [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>] doses of naloxone (<xref rid="pharmacy-11-00099-t006" ref-type="table">Table 6</xref>). No studies reported measures of program economic impact (e.g., revenue generated, return-on-investment), and few reported patient/provider satisfaction measures (<italic toggle="yes">n</italic> = 2) [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>]. Specifically, Cochran and colleagues [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>] measured patient satisfaction via post-program surveys using a Likert-type scale and found that 92.4% of participants were satisfied with the program, with a mean program rating of 4.2 out of 5. Furthermore, Teeter and colleagues [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>] performed post-program interviews with pharmacy personnel to assess program feasibility, acceptability, and appropriateness; all measures were discussed positively. Two articles reported anecdotal evidence of program satisfaction but did not report a priori measures of satisfaction via surveys, interviews, or other methods [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>].</p></sec></sec><sec sec-type="discussion" id="sec4-pharmacy-11-00099"><title>4. Discussion</title><p>This scoping review used evidence-based reporting guidelines [<xref rid="B20-pharmacy-11-00099" ref-type="bibr">20</xref>,<xref rid="B21-pharmacy-11-00099" ref-type="bibr">21</xref>] to explore the existing practice models and practice opportunities surrounding community pharmacist-delivered opioid counseling and naloxone services in the United States, with the goal of enhancing organizational readiness and improving patient access. This review fills a gap in the harm reduction literature, as limited reviews have examined opioid counseling and naloxone services in the community pharmacy setting [<xref rid="B26-pharmacy-11-00099" ref-type="bibr">26</xref>,<xref rid="B46-pharmacy-11-00099" ref-type="bibr">46</xref>], and to the authors&#8217; knowledge, this is the first review exploring community pharmacy-based OCN implementation inputs and processes in addition to outputs and outcomes. Overall, a wide variety of community pharmacy-based OCN program themes were identified throughout the articles included in this review, with several opportunities for growth identified that are related to program inputs and resources, implementation processes, and programmatic outcomes.</p><p>Specifically, seven broad program themes were identified. The themes and sub-themes occurring in the largest number of articles (<italic toggle="yes">n</italic> = 12) included one-on-one patient education and naloxone recommendation/dispensing. On the other hand, opioid therapy and pain management and group education sessions were cited the least frequently (<italic toggle="yes">n</italic> = 1). Based on this, it is evident that one-on-one patient education and naloxone recommendation/dispensing are common, widely accepted elements of community pharmacy-based OCN practice models. With that being said, there is an opportunity for community pharmacies to implement group opioid/naloxone education sessions and opioid therapy management services based on the precedents set by Akers et al. [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>] and Manzur and colleagues [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>]. In particular, given that group education sessions are equally efficacious yet more cost-effective compared to one-on-one sessions [<xref rid="B47-pharmacy-11-00099" ref-type="bibr">47</xref>,<xref rid="B48-pharmacy-11-00099" ref-type="bibr">48</xref>], this represents an effective but underutilized service that can be adopted by independently owned community pharmacies to distinguish their business in the current competitive market. Pharmacists wishing to incorporate these elements may start by contacting their local health departments and local physician offices to initiate partnerships and/or referral networks [<xref rid="B49-pharmacy-11-00099" ref-type="bibr">49</xref>].</p><p>The current review found that, in general, community pharmacy-based OCN program inputs and resources were not well described. The most commonly discussed program input involved the type of personnel/staffing used to perform the service, with in-house pharmacists being the norm across all articles. However, given that few articles described incorporating non-pharmacist personnel into their OCN service [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>], there is an opportunity for community pharmacies to further utilize pharmacy technicians, interns, and residents. In light of the increasing roles of pharmacy technicians in other services such as immunizations [<xref rid="B50-pharmacy-11-00099" ref-type="bibr">50</xref>] and medication therapy management (MTM) [<xref rid="B51-pharmacy-11-00099" ref-type="bibr">51</xref>], this represents a potential to maximize OCN service return-on-investment while freeing up pharmacists&#8217; time by assigning non-pharmacist staff to perform non-counseling tasks such as patient intake, screening, naloxone dispensing (as applicable), rooming the patient, and post-visit paperwork. Furthermore, no articles described the use of an outsourced OCN service provider, such as a clinical pharmacist who floats between multiple stores, which represents an area for further exploration and may open up novel job opportunities in the pharmacy profession, potentially increasing pharmacist job satisfaction [<xref rid="B52-pharmacy-11-00099" ref-type="bibr">52</xref>]. Along the same lines, few studies reported pharmacist FTEs involved in OCN service implementation [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>] or pharmacy facilities necessary to perform the service [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>], and none discussed expenses incurred in initiating and implementing OCN, making it difficult to come to any firm conclusions regarding the minimum number of pharmacists, types of facilities (consultation room, pick-up window, etc.), or financial investments that are required for a successful service. Following the FDA&#8217;s approval of the OTC sale of Narcan<sup>&#174;</sup>, and taking into account that other formulations of naloxone will remain prescription-only, understanding the facilities and expenses incurred in stocking and furnishing naloxone is more important than ever [<xref rid="B15-pharmacy-11-00099" ref-type="bibr">15</xref>]. However, it is important to note that, before issues of outsourcing personnel and start-up costs can be addressed, larger ongoing barriers to community pharmacy-based OCN implementation must be acknowledged and overcome. Specifically, pharmacists consistently report a lack of time, staff shortages, competing workflow priorities, and a lack of knowledge/training about opioids and naloxone as barriers to OCN service implementation [<xref rid="B16-pharmacy-11-00099" ref-type="bibr">16</xref>,<xref rid="B53-pharmacy-11-00099" ref-type="bibr">53</xref>,<xref rid="B54-pharmacy-11-00099" ref-type="bibr">54</xref>]. Gaining management support to provide additional support staff and protected time for training during work hours through the use of an OCN service &#8220;champion&#8221; may assist community pharmacy personnel in taking the first step towards mitigating these barriers [<xref rid="B55-pharmacy-11-00099" ref-type="bibr">55</xref>,<xref rid="B56-pharmacy-11-00099" ref-type="bibr">56</xref>]. Future studies should consider exploring these issues.</p><p>Compared to program inputs and resources, program implementation processes were more fully described by the included articles. For example, current successful community pharmacy-based OCN services appear to utilize in-person walk-in models [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>] making use of statewide naloxone standing orders or prescriptive authority [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>], with targeted patient identification strategies (e.g., based on CDC guidelines or other screening tools) [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>] and workflow aids such as checklists, decision guides, and instruction sheets at each workstation. However, gaps and opportunities still exist. Specifically, few pharmacies utilized an appointment-based model for OCN services [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>,<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>]. Given that appointment-based models have been shown to improve patient health outcomes (including medication adherence), increase the number of prescription fills, and reduce the number of unnecessary trips to the pharmacy [<xref rid="B57-pharmacy-11-00099" ref-type="bibr">57</xref>], the use of this model may help some pharmacies to overcome commonly reported barriers to OCN services implementation, including inconsistent reimbursement and a lack of time for performing services [<xref rid="B16-pharmacy-11-00099" ref-type="bibr">16</xref>,<xref rid="B58-pharmacy-11-00099" ref-type="bibr">58</xref>]. Furthermore, pharmacies encountering patient resistance to OCN services may consider using a universal rather than a targeted approach to patient identification. Although few studies in the current review reported using a universal approach to patient identification and communication, this approach has been shown to reduce perceptions of stigma and targeting experienced by patients [<xref rid="B59-pharmacy-11-00099" ref-type="bibr">59</xref>,<xref rid="B60-pharmacy-11-00099" ref-type="bibr">60</xref>]. The use of technology in patient intake/screening (e.g., tablets, QR codes) [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>] and identification (e.g., clinical flags in the dispensing software) [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>] has likewise been reported in few articles and represents an area for future research in the OCN services realm, as the integration of health information technology has proven successful in other services such as MTM [<xref rid="B61-pharmacy-11-00099" ref-type="bibr">61</xref>]. Lastly, although current OCN implementation processes were generally well described in most areas, business operations were not as clear. In particular, less than half of the included articles described their OCN program marketing strategies [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>,<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>,<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>,<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>,<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>], and few described their service reimbursement model [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>,<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>] or processes for evaluating service fidelity [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>]. Of those that described their service reimbursement model, both an out-of-pocket model including a counseling fee [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>] as well as third-party models focused solely on naloxone product reimbursement were reported [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>,<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>]. Pharmacies wishing to initiate or enhance their OCN services implementation may benefit from conducting a needs assessment of their client population to determine which reimbursement model is the most feasible and acceptable [<xref rid="B62-pharmacy-11-00099" ref-type="bibr">62</xref>], particularly when OTC sales of Narcan<sup>&#174;</sup> are initiated [<xref rid="B15-pharmacy-11-00099" ref-type="bibr">15</xref>]. Additionally, pharmacy personnel planning to implement OCN services may consult <xref rid="app1-pharmacy-11-00099" ref-type="app">Supplementary Table S1</xref> for a collated list of OCN resources and tools mentioned throughout this review.</p><p>In terms of programmatic outcomes, the majority of included studies reported positive effects of community pharmacy-based OCN services. Specifically, OCN services resulted in the education of thousands of patients, the provision of hundreds of doses of naloxone, opioid/pain medication-related problem identification, and associated potential decreases in opioid overdose deaths. Furthermore, few studies measured patient/provider satisfaction with OCN services, but those that did observed positive results. Given that quantified measures of patient experiences can help to identify service limitations [<xref rid="B63-pharmacy-11-00099" ref-type="bibr">63</xref>], satisfaction measures should be further examined in future studies in order to improve intervention quality and service delivery. Lastly, no studies in this review evaluated economic outcomes resulting from community pharmacy-based OCN services, and in fact, limited information regarding the economic impact exists [<xref rid="B64-pharmacy-11-00099" ref-type="bibr">64</xref>]. Acharya and colleagues demonstrated the positive cost-effectiveness of a pharmacist-based intranasal naloxone distribution intervention using a modeling process known as a Markov model [<xref rid="B65-pharmacy-11-00099" ref-type="bibr">65</xref>]. However, evaluations of the economic effects (e.g., return on investment, healthcare expenditures averted, etc.) of community pharmacy-based OCN are needed in future research in order to advance the profession of pharmacy and demonstrate the value of pharmacy services.</p><sec><title>Limitations</title><p>Several limitations of this review must be taken into account. First, although the current study identified literature from a variety of online databases including PubMed, CINAHL, IPA, and Google Scholar, we may have missed additional relevant studies present in other databases such as <uri>ClinicalTrials.gov</uri>. Second, this study only included peer-reviewed articles. Hence, on-going work that was not yet published, available in pre-print servers, or published in non-peer-reviewed editorials or websites at the time the search was conducted is not included in this review. This introduces an element of publication bias; however, the use of the aforementioned databases and peer-reviewed articles was sufficient to achieve the purpose of this scoping review: gaining a broad understanding of the community pharmacy-based OCN landscape and identifying gaps and opportunities. Third, this study was not able to report international differences in OCN programs since studies published outside of the United States and in languages other than English were excluded. Lastly, given the nature of this study as a scoping review, the quality of articles was not assessed; future systematic reviews focused on a similar topic may wish to assess article quality, although the wide variety of measures and outcomes utilized in each article may complicate this assessment.</p></sec></sec><sec sec-type="conclusions" id="sec5-pharmacy-11-00099"><title>5. Conclusions</title><p>This review may serve as a guide for community pharmacists in implementing OCN services in their own practices, highlighting areas for organizational enhancement. There is an opportunity for community pharmacists to utilize ancillary pharmacy staff, including technicians, students, and residents, to improve OCN workflow efficiency. Interprofessional collaborations and group education sessions are little-utilized program elements that could increase uptake. Future studies should clarify OCN program implementation costs, patient/provider satisfaction, and economic impact.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmacy-11-00099"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/pharmacy11030099/s1">https://www.mdpi.com/article/10.3390/pharmacy11030099/s1</uri>, Table S1: Opioid Counseling and Naloxone Service Implementation Resources and Tools.</p><supplementary-material id="pharmacy-11-00099-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmacy-11-00099-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, L.H.; methodology, L.H., K.H., Y.Z., K.M., H.P., C.C. and B.F.; software, L.H.; validation, L.H., K.H. and Y.Z.; formal analysis, L.H. and K.H.; resources, L.H.; data curation, L.H. and K.H.; writing&#8212;original draft preparation, L.H., K.H. and Y.Z.; writing&#8212;review and editing, L.H., K.H., Y.Z., K.M., H.P., C.C. and B.F.; visualization, L.H.; supervision, L.H.; project administration, L.H.; funding acquisition, L.H., K.M., H.P., C.C. and B.F. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmacy-11-00099"><label>1.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>National Institute on Drug Abuse</collab></person-group><article-title>Opioids</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/pubmed/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-15">(accessed on 15 February 2023)</date-in-citation></element-citation></ref><ref id="B2-pharmacy-11-00099"><label>2.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group><article-title>Opioid Basics</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/opioids/basics/index.html" ext-link-type="uri">https://www.cdc.gov/opioids/basics/index.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-15">(accessed on 15 February 2023)</date-in-citation></element-citation></ref><ref id="B3-pharmacy-11-00099"><label>3.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group><article-title>SUDORS Dashboard: Fatal Overdose Data</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/drugoverdose/fatal/dashboard/index.html" ext-link-type="uri">https://www.cdc.gov/drugoverdose/fatal/dashboard/index.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-27">(accessed on 27 March 2023)</date-in-citation></element-citation></ref><ref id="B4-pharmacy-11-00099"><label>4.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>US Department of Agriculture (USDA)</collab></person-group><article-title>Opioid Misuse in Rural America</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.usda.gov/topics/opioids" ext-link-type="uri">https://www.usda.gov/topics/opioids</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-15">(accessed on 15 February 2023)</date-in-citation></element-citation></ref><ref id="B5-pharmacy-11-00099"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Florence</surname><given-names>C.</given-names></name></person-group><article-title>State-level economic costs of opioid use disorder and fatal opioid overdose&#8212;United States, 2017</article-title><source>Morb. Mortal. Wkly. Rep.</source><year>2021</year><volume>70</volume><fpage>541</fpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7015a1</pub-id><pub-id pub-id-type="pmid">33857070</pub-id><pub-id pub-id-type="pmcid">PMC8344997</pub-id></element-citation></ref><ref id="B6-pharmacy-11-00099"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>L.</given-names></name></person-group><article-title>Naloxone&#8217;s role in the national opioid crisis&#8212;Past struggles, current efforts, and future opportunities</article-title><source>Transl. Res.</source><year>2021</year><volume>234</volume><fpage>43</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2021.03.001</pub-id><pub-id pub-id-type="pmid">33684591</pub-id><pub-id pub-id-type="pmcid">PMC8327685</pub-id></element-citation></ref><ref id="B7-pharmacy-11-00099"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>D.</given-names></name></person-group><article-title>State legal innovations to encourage naloxone dispensing</article-title><source>J. Am. Pharm. Assoc.</source><year>2017</year><volume>57</volume><fpage>S180</fpage><lpage>S184</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2016.11.007</pub-id><pub-id pub-id-type="pmid">28073688</pub-id></element-citation></ref><ref id="B8-pharmacy-11-00099"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>D.</given-names></name></person-group><article-title>Legal changes to increase access to naloxone for opioid overdose reversal in the United States</article-title><source>Drug Alcohol Depend.</source><year>2015</year><volume>157</volume><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.10.013</pub-id><pub-id pub-id-type="pmid">26507172</pub-id></element-citation></ref><ref id="B9-pharmacy-11-00099"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hines</surname><given-names>K.</given-names></name><name name-style="western"><surname>Garofoli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Garofoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elswick</surname><given-names>B.</given-names></name><name name-style="western"><surname>Winstanley</surname><given-names>E.</given-names></name></person-group><article-title>Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy</article-title><source>J. Am. Pharm. Assoc.</source><year>2020</year><volume>60</volume><fpage>e205</fpage><lpage>e214</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2020.07.015</pub-id><pub-id pub-id-type="pmid">32800678</pub-id></element-citation></ref><ref id="B10-pharmacy-11-00099"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akers</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Oftebro</surname><given-names>R.D.</given-names></name></person-group><article-title>Implementing take-home naloxone in an urban community pharmacy</article-title><source>J. Am. Pharm. Assoc.</source><year>2017</year><volume>57</volume><fpage>S161</fpage><lpage>S167</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2017.01.006</pub-id><pub-id pub-id-type="pmid">28202384</pub-id></element-citation></ref><ref id="B11-pharmacy-11-00099"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cariveau</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fagan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>C.</given-names></name></person-group><article-title>Evaluation of a pharmacist-led naloxone coprescribing program in primary care</article-title><source>J. Am. Pharm. Assoc.</source><year>2019</year><volume>59</volume><fpage>867</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2019.07.012</pub-id><pub-id pub-id-type="pmid">31466899</pub-id></element-citation></ref><ref id="B12-pharmacy-11-00099"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Napoli</surname><given-names>K.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>M.</given-names></name><name name-style="western"><surname>Remines</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nadpara</surname><given-names>P.</given-names></name><name name-style="western"><surname>Goode</surname><given-names>J.-V.R.</given-names></name></person-group><article-title>Impact of pharmacist counseling to enhance the accessibility of naloxone nasal spray to patients in a community pharmacy setting</article-title><source>J. Am. Pharm. Assoc.</source><year>2021</year><volume>61</volume><fpage>S127</fpage><lpage>S134</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2020.12.007</pub-id><pub-id pub-id-type="pmid">33441280</pub-id></element-citation></ref><ref id="B13-pharmacy-11-00099"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Das</surname><given-names>N.</given-names></name></person-group><article-title>Naloxone Counseling for Harm Reduction and Patient Engagement</article-title><source>Fam. Med.</source><year>2017</year><volume>49</volume><fpage>730</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">29045991</pub-id></element-citation></ref><ref id="B14-pharmacy-11-00099"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teeter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Thannisch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zaller</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mosley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Curran</surname><given-names>G.</given-names></name></person-group><article-title>Opioid overdose counseling and prescribing of naloxone in rural community pharmacies: A pilot study</article-title><source>Explor. Res. Clin. Soc. Pharm.</source><year>2021</year><volume>2</volume><fpage>100019</fpage><pub-id pub-id-type="doi">10.1016/j.rcsop.2021.100019</pub-id><pub-id pub-id-type="pmid">35128518</pub-id><pub-id pub-id-type="pmcid">PMC8813166</pub-id></element-citation></ref><ref id="B15-pharmacy-11-00099"><label>15.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Food and Drug Administration (FDA)</collab></person-group><article-title>FDA Approves First Over-the-Counter Naloxone Nasal Spray</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-29">(accessed on 29 March 2023)</date-in-citation></element-citation></ref><ref id="B16-pharmacy-11-00099"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hohmann</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Garza</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Curran</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Westrick</surname><given-names>S.C.</given-names></name></person-group><article-title>Impact of a Multicomponent Educational Intervention on Community Pharmacy&#8211;Based Naloxone Services Implementation: A Pragmatic Randomized Controlled Trial</article-title><source>Ann. Pharmacother.</source><year>2023</year><volume>57</volume><fpage>677</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1177/10600280221120405</pub-id><pub-id pub-id-type="pmid">36047381</pub-id><pub-id pub-id-type="pmcid">PMC10310292</pub-id></element-citation></ref><ref id="B17-pharmacy-11-00099"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Wyant</surname><given-names>S.L.</given-names></name></person-group><article-title>Pain management content in curricula of US schools of pharmacy</article-title><source>J. Am. Pharm. Assoc.</source><year>2003</year><volume>43</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">12585749</pub-id></element-citation></ref><ref id="B18-pharmacy-11-00099"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davenport</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Arnett</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.L.</given-names></name></person-group><article-title>Indiana community pharmacist preceptors&#8217; knowledge and perceptions of medication-assisted treatment</article-title><source>J. Am. Pharm. Assoc.</source><year>2020</year><volume>60</volume><fpage>S20</fpage><lpage>S28.e24</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2020.01.001</pub-id><pub-id pub-id-type="pmid">32094038</pub-id></element-citation></ref><ref id="B19-pharmacy-11-00099"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilkerson</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Groves</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>B.H.</given-names></name></person-group><article-title>Implementation of a naloxone dispensing program in a grocery store&#8211;based community pharmacy</article-title><source>Am. J. Health-Syst. Pharm.</source><year>2020</year><volume>77</volume><fpage>511</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1093/ajhp/zxaa006</pub-id><pub-id pub-id-type="pmid">32086505</pub-id></element-citation></ref><ref id="B20-pharmacy-11-00099"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arksey</surname><given-names>H.</given-names></name><name name-style="western"><surname>O&#8217;Malley</surname><given-names>L.</given-names></name></person-group><article-title>Scoping studies: Towards a methodological framework</article-title><source>Int. J. Soc. Res. Methodol.</source><year>2005</year><volume>8</volume><fpage>19</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1080/1364557032000119616</pub-id></element-citation></ref><ref id="B21-pharmacy-11-00099"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levac</surname><given-names>D.</given-names></name><name name-style="western"><surname>Colquhoun</surname><given-names>H.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>K.K.</given-names></name></person-group><article-title>Scoping studies: Advancing the methodology</article-title><source>Implement. Sci.</source><year>2010</year><volume>5</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/1748-5908-5-69</pub-id><pub-id pub-id-type="pmid">20854677</pub-id><pub-id pub-id-type="pmcid">PMC2954944</pub-id></element-citation></ref><ref id="B22-pharmacy-11-00099"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hohmann</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Hastings</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Curran</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Westrick</surname><given-names>S.C.</given-names></name></person-group><article-title>Medicare Annual Wellness Visits: A Scoping Review of Current Practice Models and Opportunities for Pharmacists</article-title><source>J. Pharm. Pract.</source><year>2020</year><volume>33</volume><fpage>666</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1177/0897190019847793</pub-id><pub-id pub-id-type="pmid">31232218</pub-id></element-citation></ref><ref id="B23-pharmacy-11-00099"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donabedian</surname><given-names>A.</given-names></name></person-group><article-title>Evaluating the quality of medical care</article-title><source>Milbank Q.</source><year>2005</year><volume>83</volume><fpage>691</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1111/j.1468-0009.2005.00397.x</pub-id><pub-id pub-id-type="pmid">16279964</pub-id><pub-id pub-id-type="pmcid">PMC2690293</pub-id></element-citation></ref><ref id="B24-pharmacy-11-00099"><label>24.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>ACT Academy</collab></person-group><article-title>Quality, Service Improvement and Redesign Tools: A Model for Measuring Quality Care. <italic toggle="yes">NHS Improvement Brief</italic>
<bold>2023</bold></article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.med.unc.edu/ihqi/wp-content/uploads/sites/463/2021/01/A-Model-for-Measuring-Quality-Care-NHS-Improvement-brief.pdf" ext-link-type="uri">https://www.med.unc.edu/ihqi/wp-content/uploads/sites/463/2021/01/A-Model-for-Measuring-Quality-Care-NHS-Improvement-brief.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-24">(accessed on 24 April 2023)</date-in-citation></element-citation></ref><ref id="B25-pharmacy-11-00099"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunter</surname><given-names>M.J.</given-names></name></person-group><article-title>The role of the ECHO model in outcomes research and clinical practice improvement</article-title><source>Am. J. Manag. Care</source><year>1999</year><volume>5</volume><fpage>S217</fpage><lpage>S224</lpage><pub-id pub-id-type="pmid">10387542</pub-id></element-citation></ref><ref id="B26-pharmacy-11-00099"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Hout</surname><given-names>M.C.</given-names></name></person-group><article-title>What is known about community pharmacy supply of naloxone? A scoping review</article-title><source>Int. J. Drug Policy</source><year>2016</year><volume>32</volume><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2016.02.006</pub-id><pub-id pub-id-type="pmid">26949189</pub-id></element-citation></ref><ref id="B27-pharmacy-11-00099"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cochran</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Field</surname><given-names>C.</given-names></name><name name-style="western"><surname>Seybert</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Hruschak</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jaber</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Tarter</surname><given-names>R.</given-names></name></person-group><article-title>A community pharmacy-led intervention for opioid medication misuse: A small-scale randomized clinical trial</article-title><source>Drug Alcohol Depend.</source><year>2019</year><volume>205</volume><fpage>107570</fpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2019.107570</pub-id><pub-id pub-id-type="pmid">31689641</pub-id><pub-id pub-id-type="pmcid">PMC6933550</pub-id></element-citation></ref><ref id="B28-pharmacy-11-00099"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manzur</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mirzaian</surname><given-names>E.</given-names></name><name name-style="western"><surname>Huynh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lien</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Durham</surname><given-names>M.</given-names></name></person-group><article-title>Implementation and assessment of a pilot, community pharmacy-based, opioid pain medication management program</article-title><source>J. Am. Pharm. Assoc. JAPhA</source><year>2020</year><volume>60</volume><fpage>497</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2019.11.029</pub-id><pub-id pub-id-type="pmid">31926871</pub-id></element-citation></ref><ref id="B29-pharmacy-11-00099"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skoy</surname><given-names>E.</given-names></name><name name-style="western"><surname>Eukel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Werremeyer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Strand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frenzel</surname><given-names>O.</given-names></name><name name-style="western"><surname>Steig</surname><given-names>J.</given-names></name></person-group><article-title>Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose</article-title><source>J. Am. Pharm. Assoc.</source><year>2020</year><volume>60</volume><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2019.09.003</pub-id><pub-id pub-id-type="pmid">31677933</pub-id></element-citation></ref><ref id="B30-pharmacy-11-00099"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skoy</surname><given-names>E.</given-names></name><name name-style="western"><surname>Werremeyer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Steig</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eukel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Frenzel</surname><given-names>O.</given-names></name><name name-style="western"><surname>Strand</surname><given-names>M.</given-names></name></person-group><article-title>Patient acceptance of naloxone resulting from targeted intervention from community pharmacists to prevent opioid misuse and accidental overdose</article-title><source>Subst. Abus.</source><year>2021</year><volume>42</volume><fpage>672</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1080/08897077.2020.1827126</pub-id><pub-id pub-id-type="pmid">33044896</pub-id></element-citation></ref><ref id="B31-pharmacy-11-00099"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strand</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Eukel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Frenzel</surname><given-names>O.</given-names></name><name name-style="western"><surname>Skoy</surname><given-names>E.</given-names></name><name name-style="western"><surname>Steig</surname><given-names>J.</given-names></name><name name-style="western"><surname>Werremeyer</surname><given-names>A.</given-names></name></person-group><article-title>Program evaluation of the Opioid and Naloxone Education (ONE Rx) program using the RE-AIM model</article-title><source>Res. Soc. Adm. Pharm.</source><year>2020</year><volume>16</volume><fpage>1248</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1016/j.sapharm.2019.11.016</pub-id><pub-id pub-id-type="pmid">31812501</pub-id></element-citation></ref><ref id="B32-pharmacy-11-00099"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sexton</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gatton</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Marciniak</surname><given-names>M.W.</given-names></name></person-group><article-title>A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy</article-title><source>J. Am. Pharm. Assoc.</source><year>2019</year><volume>59</volume><fpage>S95</fpage><lpage>S100</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2019.03.015</pub-id><pub-id pub-id-type="pmid">31231001</pub-id></element-citation></ref><ref id="B33-pharmacy-11-00099"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santa</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Amirova</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Ventricelli</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Downs</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Nowalk</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Pringle</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Aruru</surname><given-names>M.</given-names></name></person-group><article-title>Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order</article-title><source>Am. J. Health-Syst. Pharm. AJHP</source><year>2021</year><volume>78</volume><fpage>327</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1093/ajhp/zxaa387</pub-id><pub-id pub-id-type="pmid">33336254</pub-id></element-citation></ref><ref id="B34-pharmacy-11-00099"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strand</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Eukel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Burck</surname><given-names>S.</given-names></name></person-group><article-title>Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk</article-title><source>Res. Soc. Adm. Pharm.</source><year>2019</year><volume>15</volume><fpage>1032</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1016/j.sapharm.2018.07.011</pub-id><pub-id pub-id-type="pmid">30031696</pub-id></element-citation></ref><ref id="B35-pharmacy-11-00099"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowell</surname><given-names>D.</given-names></name></person-group><article-title>CDC Clinical Practice Guideline for Prescribing Opioids for Pain&#8212;United States, 2022</article-title><source>MMWR Recomm. Rep.</source><year>2022</year><volume>71</volume><fpage>1</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.15585/mmwr.rr7103a1</pub-id><pub-id pub-id-type="pmcid">PMC9639433</pub-id><pub-id pub-id-type="pmid">36327391</pub-id></element-citation></ref><ref id="B36-pharmacy-11-00099"><label>36.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Substance Abuse and Mental Health Services Administration (SAMHSA)</collab></person-group><article-title>Opioid Overdose Prevention Toolkit</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.samhsa.gov/resource/ebp/opioid-overdose-prevention-toolkit" ext-link-type="uri">https://www.samhsa.gov/resource/ebp/opioid-overdose-prevention-toolkit</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-11-16">(accessed on 16 November 2022)</date-in-citation></element-citation></ref><ref id="B37-pharmacy-11-00099"><label>37.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Prescribe to Prevent</collab></person-group><article-title>Prescribe Naloxone, Save a Life</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.prescribetoprevent.com/" ext-link-type="uri">https://www.prescribetoprevent.com/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-11-16">(accessed on 16 November 2022)</date-in-citation></element-citation></ref><ref id="B38-pharmacy-11-00099"><label>38.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>T.</given-names></name></person-group><article-title>Maximizing OpiOid Safety with Naloxone (MOON) Study. Boston Medical Center</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bmc.org/research/maximizing-opioid-safety-naloxone-moon-study" ext-link-type="uri">https://www.bmc.org/research/maximizing-opioid-safety-naloxone-moon-study</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-07">(accessed on 7 February 2023)</date-in-citation></element-citation></ref><ref id="B39-pharmacy-11-00099"><label>39.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Washington State Agency Medical Directors Group</collab></person-group><article-title>Interagency Guideline on Prescribing Opioids for Pain</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf" ext-link-type="uri">https://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-08">(accessed on 8 February 2023)</date-in-citation></element-citation></ref><ref id="B40-pharmacy-11-00099"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knisely</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Wunsch</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Cropsey</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>E.D.</given-names></name></person-group><article-title>Prescription Opioid Misuse Index: A brief questionnaire to assess misuse</article-title><source>J. Subst. Abus. Treat.</source><year>2008</year><volume>35</volume><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2008.02.001</pub-id><pub-id pub-id-type="pmid">18657935</pub-id></element-citation></ref><ref id="B41-pharmacy-11-00099"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Webster</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>R.M.</given-names></name></person-group><article-title>Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool</article-title><source>J. Pain Med.</source><year>2005</year><volume>6</volume><fpage>432</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4637.2005.00072.x</pub-id><pub-id pub-id-type="pmid">16336480</pub-id></element-citation></ref><ref id="B42-pharmacy-11-00099"><label>42.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>OneRx</collab></person-group><article-title>Opioid and Naloxone Education</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://one-program.org/" ext-link-type="uri">https://one-program.org/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-08">(accessed on 8 February 2023)</date-in-citation></element-citation></ref><ref id="B43-pharmacy-11-00099"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shonesy</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dorval</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gitlow</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gustin</surname><given-names>R.M.</given-names></name></person-group><article-title>Screening, Brief Intervention, and Referral to Treatment (SBIRT) in a retail pharmacy setting: The pharmacist&#8217;s role in identifying and addressing risk of substance use disorder</article-title><source>J. Addict. Med.</source><year>2019</year><volume>13</volume><fpage>403</fpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000000525</pub-id><pub-id pub-id-type="pmid">30870202</pub-id><pub-id pub-id-type="pmcid">PMC6733670</pub-id></element-citation></ref><ref id="B44-pharmacy-11-00099"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krebs</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Lorenz</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Bair</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Damush</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sutherland</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Asch</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kroenke</surname><given-names>K.</given-names></name></person-group><article-title>Development and Initial Validation of the PEG, a Three-item Scale Assessing Pain Intensity and Interference</article-title><source>J. Gen. Intern. Med.</source><year>2009</year><volume>24</volume><fpage>733</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1007/s11606-009-0981-1</pub-id><pub-id pub-id-type="pmid">19418100</pub-id><pub-id pub-id-type="pmcid">PMC2686775</pub-id></element-citation></ref><ref id="B45-pharmacy-11-00099"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroenke</surname><given-names>K.</given-names></name><name name-style="western"><surname>Spitzer</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.B.</given-names></name></person-group><article-title>The PHQ-9: Validity of a brief depression severity measure</article-title><source>J. Gen. Intern. Med.</source><year>2001</year><volume>16</volume><fpage>606</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1046/j.1525-1497.2001.016009606.x</pub-id><pub-id pub-id-type="pmid">11556941</pub-id><pub-id pub-id-type="pmcid">PMC1495268</pub-id></element-citation></ref><ref id="B46-pharmacy-11-00099"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Daskalakis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grindrod</surname><given-names>K.</given-names></name><name name-style="western"><surname>Beazely</surname><given-names>M.A.</given-names></name></person-group><article-title>What is known about community pharmacy-based take-home naloxone programs and program interventions? A scoping review</article-title><source>Pharmacy</source><year>2021</year><volume>9</volume><elocation-id>30</elocation-id><pub-id pub-id-type="doi">10.3390/pharmacy9010030</pub-id><pub-id pub-id-type="pmid">33540676</pub-id><pub-id pub-id-type="pmcid">PMC7931101</pub-id></element-citation></ref><ref id="B47-pharmacy-11-00099"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Jaffee</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>de Menil</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Cogley</surname><given-names>C.B.</given-names></name></person-group><article-title>Group therapy for substance use disorders: What do we know?</article-title><source>Harv. Rev. Psychiatry</source><year>2004</year><volume>12</volume><fpage>339</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1080/10673220490905723</pub-id><pub-id pub-id-type="pmid">15764469</pub-id></element-citation></ref><ref id="B48-pharmacy-11-00099"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastien</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Morin</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ouellet</surname><given-names>M.-C.</given-names></name><name name-style="western"><surname>Blais</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Bouchard</surname><given-names>S.</given-names></name></person-group><article-title>Cognitive-behavioral therapy for insomnia: Comparison of individual therapy, group therapy, and telephone consultations</article-title><source>J. Consult. Clin. Psychol.</source><year>2004</year><volume>72</volume><fpage>653</fpage><pub-id pub-id-type="doi">10.1037/0022-006X.72.4.653</pub-id><pub-id pub-id-type="pmid">15301650</pub-id></element-citation></ref><ref id="B49-pharmacy-11-00099"><label>49.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>J.S.</given-names></name></person-group><article-title>Building a Legally Compliant Referral Network. <italic toggle="yes">Pharmacy Times</italic>
<bold>2018</bold></article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pharmacytimes.com/view/building-a-legally-compliant-referral-network-" ext-link-type="uri">https://www.pharmacytimes.com/view/building-a-legally-compliant-referral-network-</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-04">(accessed on 4 April 2023)</date-in-citation></element-citation></ref><ref id="B50-pharmacy-11-00099"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKeirnan</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Frazier</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M.</given-names></name><name name-style="western"><surname>MacLean</surname><given-names>L.G.</given-names></name></person-group><article-title>Training pharmacy technicians to administer immunizations</article-title><source>J. Am. Pharm. Assoc.</source><year>2018</year><volume>58</volume><fpage>174</fpage><lpage>178.e171</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2018.01.003</pub-id><pub-id pub-id-type="pmid">29459094</pub-id></element-citation></ref><ref id="B51-pharmacy-11-00099"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hohmeier</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>McDonough</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Rein</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Brookhart</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Powers</surname><given-names>M.F.</given-names></name></person-group><article-title>Exploring the expanded role of the pharmacy technician in medication therapy management service implementation in the community pharmacy</article-title><source>J. Am. Pharm. Assoc.</source><year>2019</year><volume>59</volume><fpage>187</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2018.11.006</pub-id><pub-id pub-id-type="pmid">30679031</pub-id></element-citation></ref><ref id="B52-pharmacy-11-00099"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fadare</surname><given-names>O.O.</given-names></name><name name-style="western"><surname>Doucette</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Gaither</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Schommer</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Arya</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bakken</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Kreling</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Mott</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Witry</surname><given-names>M.J.</given-names></name></person-group><article-title>Exploring the moderating role of job resources in how job demands influence burnout and professional fulfillment among US pharmacists</article-title><source>Res. Soc. Adm. Pharm.</source><year>2022</year><volume>18</volume><fpage>3821</fpage><lpage>3830</lpage><pub-id pub-id-type="doi">10.1016/j.sapharm.2022.04.003</pub-id><pub-id pub-id-type="pmid">35466066</pub-id></element-citation></ref><ref id="B53-pharmacy-11-00099"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudolph</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Branham</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Moose</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Marciniak</surname><given-names>M.W.</given-names></name></person-group><article-title>Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina</article-title><source>J. Am. Pharm. Assoc.</source><year>2018</year><volume>58</volume><fpage>S55</fpage><lpage>S58.e53</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2018.04.025</pub-id><pub-id pub-id-type="pmid">30006187</pub-id></element-citation></ref><ref id="B54-pharmacy-11-00099"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thornton</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Lyvers</surname><given-names>E.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Dwibedi</surname><given-names>N.</given-names></name></person-group><article-title>Pharmacists&#8217; readiness to provide naloxone in community pharmacies in West Virginia</article-title><source>J. Am. Pharm. Assoc.</source><year>2017</year><volume>57</volume><fpage>S12</fpage><lpage>S18.e14</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2016.12.070</pub-id><pub-id pub-id-type="pmid">28163027</pub-id><pub-id pub-id-type="pmcid">PMC5352525</pub-id></element-citation></ref><ref id="B55-pharmacy-11-00099"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gattiker</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>C.R.</given-names></name></person-group><article-title>Understanding project champions&#8217; ability to gain intra-organizational commitment for environmental projects</article-title><source>J. Oper. Manag.</source><year>2010</year><volume>28</volume><fpage>72</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.jom.2009.09.001</pub-id></element-citation></ref><ref id="B56-pharmacy-11-00099"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waltz</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Matthieu</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Damschroder</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Chinman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Proctor</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Kirchner</surname><given-names>J.E.</given-names></name></person-group><article-title>Use of concept mapping to characterize relationships among implementation strategies and assess their feasibility and importance: Results from the Expert Recommendations for Implementing Change (ERIC) study</article-title><source>Implement. Sci.</source><year>2015</year><volume>10</volume><fpage>109</fpage><pub-id pub-id-type="doi">10.1186/s13012-015-0295-0</pub-id><pub-id pub-id-type="pmid">26249843</pub-id><pub-id pub-id-type="pmcid">PMC4527340</pub-id></element-citation></ref><ref id="B57-pharmacy-11-00099"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hincapie</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Luder</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frede</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heaton</surname><given-names>P.C.</given-names></name></person-group><article-title>Appointment-based models: A comparison of three model designs in a large chain community pharmacy setting</article-title><source>J. Am. Pharm. Assoc.</source><year>2018</year><volume>58</volume><fpage>156</fpage><lpage>162.e151</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2018.01.005</pub-id><pub-id pub-id-type="pmid">29506660</pub-id></element-citation></ref><ref id="B58-pharmacy-11-00099"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thakur</surname><given-names>T.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chewning</surname><given-names>B.</given-names></name></person-group><article-title>Pharmacist roles, training, and perceived barriers in naloxone dispensing: A systematic review</article-title><source>J. Am. Pharm. Assoc.</source><year>2020</year><volume>60</volume><fpage>178</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2019.06.016</pub-id><pub-id pub-id-type="pmid">31371179</pub-id></element-citation></ref><ref id="B59-pharmacy-11-00099"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hohmann</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Krauss</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marley</surname><given-names>G.T.</given-names></name></person-group><article-title>Public Perceptions of Community Pharmacy-Based Naloxone Services: A National Cross-Sectional Survey</article-title><source>Pharmacy</source><year>2022</year><volume>10</volume><elocation-id>171</elocation-id><pub-id pub-id-type="doi">10.3390/pharmacy10060171</pub-id><pub-id pub-id-type="pmid">36548327</pub-id><pub-id pub-id-type="pmcid">PMC9781939</pub-id></element-citation></ref><ref id="B60-pharmacy-11-00099"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Case</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fiske</surname><given-names>H.</given-names></name><name name-style="western"><surname>Baird</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>S.</given-names></name><name name-style="western"><surname>Burstein</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>V.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Walley</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Bratberg</surname><given-names>J.</given-names></name></person-group><article-title>Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states</article-title><source>J. Am. Pharm. Assoc.</source><year>2017</year><volume>57</volume><fpage>S19</fpage><lpage>S27.e14</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2017.01.013</pub-id><pub-id pub-id-type="pmid">28214219</pub-id></element-citation></ref><ref id="B61-pharmacy-11-00099"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMahan</surname><given-names>R.</given-names></name></person-group><article-title>Operationalizing MTM through the use of health information technology</article-title><source>J. Manag. Care Pharm.</source><year>2008</year><volume>14</volume><fpage>S18</fpage><pub-id pub-id-type="pmid">18331116</pub-id></element-citation></ref><ref id="B62-pharmacy-11-00099"><label>62.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Soriano</surname><given-names>F.I.</given-names></name></person-group><source>Conducting Needs Assessments: A Multidisciplinary Approach</source><publisher-name>SAGE Publications</publisher-name><publisher-loc>Thousand Oaks, CA, USA</publisher-loc><year>2012</year><volume>Volume 68</volume></element-citation></ref><ref id="B63-pharmacy-11-00099"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>K.</given-names></name><name name-style="western"><surname>Udogwu</surname><given-names>U.N.</given-names></name><name name-style="western"><surname>Manson</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Banagan</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yousaf</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Yousaf</surname><given-names>O.</given-names></name><name name-style="western"><surname>Demyanovich</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pollak</surname><given-names>A.N.</given-names></name><etal/></person-group><article-title>Patient Satisfaction after Discharge Is Discordant with Reported Inpatient Experience</article-title><source>Orthopedics</source><year>2021</year><volume>44</volume><fpage>e427</fpage><lpage>e433</lpage><pub-id pub-id-type="doi">10.3928/01477447-20210415-01</pub-id><pub-id pub-id-type="pmid">34039209</pub-id></element-citation></ref><ref id="B64-pharmacy-11-00099"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanyal</surname><given-names>C.</given-names></name></person-group><article-title>Economic burden of opioid crisis and the role of pharmacist-led interventions</article-title><source>J. Am. Pharm. Assoc.</source><year>2021</year><volume>61</volume><fpage>e70</fpage><lpage>e74</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2020.11.006</pub-id><pub-id pub-id-type="pmid">33279425</pub-id></element-citation></ref><ref id="B65-pharmacy-11-00099"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acharya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Teeter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>B.C.</given-names></name></person-group><article-title>Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users</article-title><source>Value Health</source><year>2020</year><volume>23</volume><fpage>451</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2019.12.002</pub-id><pub-id pub-id-type="pmid">32327162</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmacy-11-00099-f001" orientation="portrait"><label>Figure 1</label><caption><p>Flow diagram of study selection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmacy-11-00099-g001.jpg"/></fig><table-wrap position="float" id="pharmacy-11-00099-t001" orientation="portrait"><object-id pub-id-type="pii">pharmacy-11-00099-t001_Table 1</object-id><label>Table 1</label><caption><p>Example search string.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Database <sup>a</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Key Words</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PubMed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(pharmacist or pharmacy) and ((opioid or opiate) or naloxone) and (counseling or service or program) and (resource or input or personnel or process or workflow or intervention or financial or economic or satisfaction) and ((develop or development) or (uptake or delivery) or planning) and (implement or implementation)</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Limits: English, 2012&#8211;2022.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmacy-11-00099-t002" orientation="portrait"><object-id pub-id-type="pii">pharmacy-11-00099-t002_Table 2</object-id><label>Table 2</label><caption><p>Study characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Setting</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Period</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Population</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Akers et al., 2017 [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Program evaluation, single-arm retrospective cohort</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Community pharmacy. Kelley-Ross Pharmacy Group, Seattle, WA.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012&#8211;2016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bystanders (family and friends), median age 57 years</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cochran et al., 2019 [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Randomized controlled trial (RCT)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two community pharmacies located in southwestern Pennsylvania, one associated with an academic medical center and the other an independent pharmacy in a rural county.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017&#8211;2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults aged 18 or older receiving prescription opioid therapy.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Manzur et al., 2020 [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Program evaluation, single-arm retrospective cohort</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Community pharmacy in an academic medical center, CA.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016&#8211;2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients enrolled were prescribed opioids for chronic pain by a rheumatology clinic and at a high risk of an opioid overdose</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skoy et al., 2020a [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Program evaluation, one-group pretest&#8211;posttest (pre&#8211;post intervention)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Community pharmacy in North Dakota.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018&#8211;2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All patients prescribed opioids</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4b</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skoy et al., 2020b [<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Program evaluation, one-group pretest&#8211;posttest (pre&#8211;post intervention)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Community pharmacy in North Dakota.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018&#8211;2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All patients prescribed opioids</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strand et al., 2020 [<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Program evaluation, one-group pretest&#8211;posttest (pre&#8211;post intervention)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A total of 149 community pharmacies in North Dakota.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018&#8211;2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All patients prescribed opioids</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strand et al., 2019 [<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Program evaluation, one-group posttest (post-intervention)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A total of 11 independent community pharmacies in North Dakota.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017&#8211;2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All patients prescribed opioids</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wilkerson et al., 2020 [<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Program evaluation, single-arm retrospective cohort</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kroger community pharmacies, Ohio. A total of 114 pharmacies in the Columbus Division and 102 pharmacies in the Cincinnati Division.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016&#8211;2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Individuals prescribed opioids and at a high risk of an opioid overdose, or those who request naloxone.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hines et al., 2020 [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Program evaluation, one-group pretest&#8211;posttest (pre&#8211;post intervention)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Independent community pharmacy in West Virginia.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 January 2019 to 15 February 2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients receiving buprenorphine-containing prescriptions for opioid use disorder (OUD).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sexton et al., 2019 [<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two-group non-randomized controlled trial </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two Kroger community pharmacies, North Carolina.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017&#8211;2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Individuals prescribed opioids and at a high risk of an opioid overdose.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Teeter et al., 2021 [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two-group non-randomized controlled trial (explanatory sequential mixed-methods)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two intervention pharmacies and two rural pharmacies within the Harps community pharmacy chain, Arkansas </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019&#8211;2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Individuals prescribed opioids and at a high risk of an opioid overdose.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Santa et al., 2021 [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">One-group pretest&#8211;posttest (pre&#8211;post educational intervention)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A total of 11 community pharmacies (chain and independent) in Philadelphia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">July 2019&#8211;December 2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All patients prescribed opioids</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmacy-11-00099-t003" orientation="portrait"><object-id pub-id-type="pii">pharmacy-11-00099-t003_Table 3</object-id><label>Table 3</label><caption><p>Program themes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Study</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Interprofessional Collaboration</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Patient Education Format</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Non-Pharmacist Provider Education</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Pharmacy Staff Education</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Opioid Misuse Screening Tool</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Naloxone Recommendation/Dispensing</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Opioid Therapy and Pain Management</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">One-on-One Patient Education</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Group Education Sessions</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Akers et al., 2017 [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cochran et al., 2019 [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Manzur et al., 2020 [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skoy et al., 2020a [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skoy et al., 2020b [<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strand et al., 2020 [<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strand et al., 2019 [<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wilkerson et al., 2020 [<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hines et al., 2020 [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sexton et al., 2019 [<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Teeter et al., 2021 [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Santa et al., 2021 [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">x</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmacy-11-00099-t004" orientation="portrait"><object-id pub-id-type="pii">pharmacy-11-00099-t004_Table 4</object-id><label>Table 4</label><caption><p>Program inputs and resources.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Study</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Inputs and Resources</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OCN Personnel</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacist FTEs for OCN</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OCN Facilities and Expenses</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Akers et al., 2017 [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacist plus technicians and assistants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">One</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients were &#8220;roomed&#8221;; additional information not reported </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cochran et al., 2019 [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Staff pharmacist, study pharmacist, and navigator (researcher)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Manzur et al., 2020 [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical pharmacist, pharmacy resident</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients seen in a private exam room in adjacent clinical suites of a community pharmacy</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skoy et al., 2020a [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skoy et al., 2020b [<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strand et al., 2020 [<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strand et al., 2019 [<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wilkerson et al., 2020 [<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacists, interns, technicians</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Note reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hines et al., 2020 [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacy resident</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Private counseling area</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sexton et al., 2019 [<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacist, student pharmacist, technician</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Teeter et al., 2021 [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Santa et al., 2021 [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmacy-11-00099-t005" orientation="portrait"><object-id pub-id-type="pii">pharmacy-11-00099-t005_Table 5</object-id><label>Table 5</label><caption><p>Program implementation processes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pharmacist Authority</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patient Identification</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pharmacist Interventions</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Workflow</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Business Operations</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Akers et al., 2017 [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Collaborative drug therapy agreement (CDTA) allowed pharmacists to initiate or modify therapy.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Communication strategy: General advertisement.</p></list-item><list-item><p>Identification process: Technicians or clerks provide general information on program availability.</p></list-item><list-item><p>Screening tool: not reported.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Type of service/intervention: Take-home naloxone program (THN) + education (individual, group, community, providers).</p></list-item><list-item><p>Intervention details: Dispensed naloxone; provided education on naloxone administration and how to manage opioid overdoses.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Time: 20 min sessions.</p></list-item><list-item><p>Setting: In-person.</p></list-item><list-item><p>Materials: Patient intake form; video; standardized checklist.</p></list-item><list-item><p>Model: Walk-in or appointment.</p></list-item><list-item><p>Roles and processes: (Technician or clerk) Patient intake form completed. Patient roomed. (Pharmacist) Review pricing. Confirm preferred delivery method of naloxone for patient (IN or IM). (Technician or clerk) During video, prescription is processed by staff. (Pharmacist) Checklist reviewed with patient. (Technician or clerk) Naloxone dispensed and payment collected.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Marketing: Marketing to bystanders (details not reported).</p></list-item><list-item><p>Formalized policies and procedures: Figure developed to clarify staff roles.</p></list-item><list-item><p>External collaborators: Partnered with Seattle-King County Public Health Department for CDTA and naloxone distribution.</p></list-item><list-item><p>Pricing/reimbursement model: Out-of-pocket pricing. Prices in internal documents for staff awareness. Price included two doses of naloxone, a counseling fee, and other materials (nasal atomizer, breathing mask, etc.).</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cochran et al., 2019 [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Not reported.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Communication strategy: Targeted offer.</p></list-item><list-item><p>Identification process: Potential participants were approached in person by the pharmacist, technician, or researcher at the point-of-service if they were prescribed an opioid medication.</p></list-item><list-item><p>Screening tool: Screened for prescription opioid misuse using the Prescription Opioid Misuse Index (POMI).</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Type of service/intervention: Brief Motivational Intervention&#8211;Medication Therapy Management (BMI-MTM).</p></list-item><list-item><p>Intervention details: Participants assigned to standard medication counseling (SMC) or SMC + BMI-MTM. BMI-MTM consisted of one pharmacist-led medication counseling/brief motivational session and eight weekly patient navigation sessions.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Time: 30&#8211;45 min.</p></list-item><list-item><p>Setting: In-person (<italic toggle="yes">n</italic> = 1) and telephone (<italic toggle="yes">n</italic> = 8).</p></list-item><list-item><p>Materials: Not reported.</p></list-item><list-item><p>Model: Appointment.</p></list-item><list-item><p>Roles and processes: (Pharmacist, technician, researcher) Screening. (Pharmacist) 30&#8211;45 min in-person BMI session. (Patient navigator who is a master&#8217;s level researcher) Eight patient navigation sessions via telephone; includes naloxone recommendation. (Pharmacist) Written summary of recommendations to patient and warm handoff to study navigator.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Manzur et al., 2020 [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>No collaborative practice agreements.</p></list-item><list-item><p>Consultation service with referring providers only.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Communication strategy: Targeted offer.</p></list-item><list-item><p>Identification process: Rheumatology clinic patients prescribed opioids were identified by a community pharmacist or clinic provider as &#8220;high risk&#8221; and referred to the pilot program if they were prescribed (based on CDC guidelines): more than 1 short-acting opioid; more than 90 morphine milligram equivalents/day; more than 7 days&#8217; supply of medications for acute pain; and high-risk medication combinations.</p></list-item><list-item><p>Screening tool: Opioid Risk Tool (ORT).</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Type of service/intervention: Pain medication management.</p></list-item><list-item><p>Intervention details: Pharmacists assessed pain management and associated concomitant disease states and provided medication recommendations to referring provider. They also performed opioid risk mitigation strategies including ORT, naloxone education, naloxone prescription, PDMP review, pain score assessment, pain medication counseling, and pain management education.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Time: 45 min.</p></list-item><list-item><p>Setting: In-person</p></list-item><list-item><p>Materials: Not reported.</p></list-item><list-item><p>Model: Appointment.</p></list-item><list-item><p>Roles and processes: (Pharmacist or resident) Opioid risk mitigation strategies performed prior to prescriber visit.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Marketing: Not reported.</p></list-item><list-item><p>Formalized policies and procedures: Not reported.</p></list-item><list-item><p>External collaborators: Nearby rheumatology clinic.</p></list-item><list-item><p>Pricing/reimbursement model: Grant-funded program; visits free for patients.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skoy et al., 2020a <sup>a</sup> [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Pharmacist authority to prescribe naloxone in North Dakota since 1 April 2017.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Communication strategy: Targeted offer.</p></list-item><list-item><p>Identification process: Each patient receiving an opioid prescription was screened for risk of opioid misuse and risk of accidental overdose based on age, concurrent medication and alcohol use, and disease states.</p></list-item><list-item><p>Screening tool: Opioid Risk Tool (ORT).</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Type of service/intervention: Opioid overdose education and naloxone distribution (OEND) + drug take-back + referral to community resources.</p></list-item><list-item><p>Intervention details: The multicomponent statewide One Rx program included drug take-back, partial fills of opioid prescriptions, referral to community resources, naloxone education and dispensing, opioid use disorder (OUD) education, accidental overdose education, and contacting the primary healthcare provider as needed.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Time: 5 min.</p></list-item><list-item><p>Setting: In-person.</p></list-item><list-item><p>Materials: Welcome packet with One Rx toolkit via hardcopy binder and website; screening tool via paper, QR code, or tablet; triage tool.</p></list-item><list-item><p>Model: Walk-in.</p></list-item><list-item><p>Roles and processes: (Pharmacist) Patient screening and PDMP review prior to prescription pick-up, followed by education and intervention guided by a triage tool and ORT score.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Marketing: Pharmacist button advertising naloxone; window sticker; emails from Board of Pharmacy; television and newspaper interviews.</p></list-item><list-item><p>Formalized policies and procedures: One Rx binder and website detailing screening, interventions, and workflow.</p></list-item><list-item><p>External collaborators: North Dakota Board of Pharmacy.</p></list-item><list-item><p>Pricing/reimbursement model: Funded by North Dakota Department of Human Services; USD 20 provided to pharmacies for each screening. Pharmacy awards for meeting screening benchmarks. Patient pricing model not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skoy et al., 2020b <sup>a</sup> [<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Pharmacist authority to prescribe naloxone in North Dakota since 1 April 2017.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Communication strategy: Targeted offer.</p></list-item><list-item><p>Identification process: Each patient receiving an opioid prescription was screened for the risk of opioid misuse and the risk of an accidental overdose based on age, concurrent medication and alcohol use, and disease states.</p></list-item><list-item><p>Screening tool: Opioid Risk Tool (ORT).</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Type of service/intervention: Opioid overdose education and naloxone distribution (OEND) + drug take-back + referral to community resources.</p></list-item><list-item><p>Intervention details: The multicomponent statewide One Rx program included drug take-back, partial fills of opioid prescriptions, referral to community resources, naloxone education and dispensing, OUD education, accidental overdose education, and contacting the primary healthcare provider as needed.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Not reported in this article; see Skoy et al. 2020a.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Marketing: Not reported.</p></list-item><list-item><p>Formalized policies and procedures: Not reported.</p></list-item><list-item><p>External collaborators: Not reported.</p></list-item><list-item><p>Pricing/reimbursement model: Naloxone product reimbursed via patient insurance or grant funds; 72% of patients received naloxone at no cost. Further details not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strand et al., 2020 <sup>a</sup> [<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Pharmacist authority to prescribe naloxone in North Dakota since 1 April 2017.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Communication strategy: Targeted offer.</p></list-item><list-item><p>Identification process: Each patient receiving an opioid prescription was screened for risk of opioid misuse and risk of accidental overdose based on age, concurrent medication and alcohol use, and disease states.</p></list-item><list-item><p>Screening tool: Opioid Risk Tool (ORT).</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Type of service/intervention: Opioid overdose education and naloxone distribution (OEND) + drug take-back + referral to community resources.</p></list-item><list-item><p>Intervention details: The multicomponent statewide One Rx program included drug take-back, partial fills of opioid prescriptions, referral to community resources, naloxone education and dispensing, OUD education, accidental overdose education, and contacting the primary healthcare provider, as needed.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Time: Not reported in this article; see Skoy et al. 2020a.</p></list-item><list-item><p>Setting: Not reported.</p></list-item><list-item><p>Materials: Welcome packet with One Rx toolkit via hardcopy binder and website; screening tool via paper, QR code, or tablet; triage tool.</p></list-item><list-item><p>Model: Not reported.</p></list-item><list-item><p>Roles and processes: Not reported.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Marketing: Emails from Board of Pharmacy; press conference.</p></list-item><list-item><p>Formalized policies and procedures: One Rx binder and website detailing screening, interventions, and workflow.</p></list-item><list-item><p>External collaborators: North Dakota Board of Pharmacy.</p></list-item><list-item><p>Pricing/reimbursement model: Funded by North Dakota Department of Human Services; USD 20 provided to pharmacies for each screening. Pharmacy awards for meeting screening benchmarks. Patient pricing model not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strand et al., 2019 <sup>a</sup> [<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Pharmacist authority to prescribe naloxone in North Dakota since 1 April 2017.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Communication strategy: Targeted offer.</p></list-item><list-item><p>Identification process: Each patient receiving an opioid prescription was screened for risk of opioid misuse and risk of accidental overdose based on age, concurrent medication and alcohol use, and disease states.</p></list-item><list-item><p>Screening tool: Opioid Risk Tool (ORT).</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Type of service/intervention: Opioid overdose education and naloxone distribution (OEND) + drug take-back + referral to community resources.</p></list-item><list-item><p>Intervention details: One Rx interventions were piloted prior to scaling up statewide, including drug take-back, partial fills of opioid prescriptions, referral to community resources, naloxone education and dispensing, OUD education, accidental overdose education, and contacting the primary healthcare provider, as needed.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Time: Not reported.</p></list-item><list-item><p>Setting: In-person.</p></list-item><list-item><p>Materials: Opioid Misuse Risk Prevention Toolkit, including paper patient intake form, ORT, and triage tool, list of community resources, and naloxone and opioid misuse educational brochures.</p></list-item><list-item><p>Model: Walk-in.</p></list-item><list-item><p>Roles and processes: (Pharmacist) Patient screening, PDMP review, and &#8220;red flag&#8221; review prior to prescription pick-up, followed by education and intervention guided by a triage tool and ORT score.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Marketing: Naloxone sign and brochures.</p></list-item><list-item><p>Formalized policies and procedures: Triage tool for guiding decision making.</p></list-item><list-item><p>External collaborators: North Dakota Board of Pharmacy.</p></list-item><list-item><p>Pricing/reimbursement model: Not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wilkerson et al., 2020 [<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Protocol approved by local physician.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Communication strategy: Targeted off and general advertisement.</p></list-item><list-item><p>Identification process: Patients at an increased risk of overdose identified by a pharmacist or intern at prescription drop-off based on criteria: high-dose opioids (&gt; 80 MME) for chronic pain, history of OUD, and concomitant conditions (respiratory, renal, hepatic). Additionally, patient request.</p></list-item><list-item><p>Screening tool: not reported.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Type of service/intervention: OEND.</p></list-item><list-item><p>Intervention details: Naloxone dispensing; opioid overdose counseling.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Time: Not reported.</p></list-item><list-item><p>Setting: In-person.</p></list-item><list-item><p>Materials: Patient naloxone consent form (checklist); patient naloxone education brochure created by the state pharmacy board.</p></list-item><list-item><p>Model: Walk-in.</p></list-item><list-item><p>Roles and processes:</p></list-item><list-item><p>(Pharmacist or intern) Identify at-risk patients at drop-off. (Pharmacist or intern) Patient fills out naloxone consent form. (Pharmacist or intern) Review consent form and naloxone dosage forms. (Technician) Naloxone prescription processed using a consent form as a prescription, prescriber on protocol, and name of individual requesting naloxone. (Technician) Naloxone prescription filled. (Pharmacist) Perform final check of naloxone prescription and add counseling note. (Pharmacist or intern) Review consent form and counsel on naloxone and opioid overdose at pick-up. Initial consent form, scan into dispensing system, and file with prescriptions.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Marketing: Naloxone sign outside pharmacy.</p></list-item><list-item><p>Formalized policies and procedures: Program designed at corporate/clinical team level and rolled out to pharmacies with a &#8220;best practices&#8221; document.</p></list-item><list-item><p>External collaborators: Not reported.</p></list-item><list-item><p>Pricing/reimbursement model: Not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hines et al., 2020 [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>West Virginia standing order.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Communication strategy: Universal offer.</p></list-item><list-item><p>Identification process: All patients receiving a buprenorphine prescription.</p></list-item><list-item><p>Screening tool: not reported.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Type of service/intervention: OEND.</p></list-item><list-item><p>Intervention details: Patients receiving buprenorphine recruited for OEND. OEND included naloxone dispensing, education on recognizing opioid overdose, identifying opioid medications, and where to obtain naloxone.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Time: 5&#8211;20 min (10 min on average).</p></list-item><list-item><p>Setting: In-person.</p></list-item><list-item><p>Materials: Educational brochure from West Virginia naloxone protocol.</p></list-item><list-item><p>Model: Walk-in.</p></list-item><list-item><p>Roles and processes: (Pharmacy staff) Patients identified at prescription drop-off or pick-up and asked about interest in OEND. Interested patients moved to private counseling area. (Pharmacy resident) Opioid overdose education provided while waiting for buprenorphine prescription. Naloxone dispensed subsequent to obtaining a prescription from the patient&#8217;s provider; standing order not available for use during study period.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Marketing: Not reported.</p></list-item><list-item><p>Formalized policies and procedures: None during the study period; resident developed business plan post-program (details not reported).</p></list-item><list-item><p>External collaborators: Not reported.</p></list-item><list-item><p>Pricing/reimbursement model: Naloxone product reimbursement via patient insurance.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sexton et al., 2019 [<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Statewide standing order.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Communication strategy: Targeted offer.</p></list-item><list-item><p>Identification process: Clinical flag placed in the dispensing system to alert the pharmacist to speak with the patient at pick-up if patients had (based on CDC guidelines): an opioid prescription in the past 30 days; opioid prescription lasting &#8805; 5 days; greater than or equal to 50 morphine milligram equivalents per day; concurrent benzodiazepine and opioid use; fentanyl patch greater than or equal to 25 mg/hour; and documented or verbal history of overdose or substance use disorder.</p></list-item><list-item><p>Screening tool: not reported.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Type of service/intervention: OEND.</p></list-item><list-item><p>Intervention details: One pharmacy implemented a standardized team-based approach (intervention); one pharmacy used the standard of practice (control). OEND included naloxone dispensing and education on opioid risks and naloxone benefits.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Time: Not reported.</p></list-item><list-item><p>Setting: In-person.</p></list-item><list-item><p>Materials: List of opioids at drop-off station; one-page instruction sheet at each workstation using colored paper; MME conversion chart; naloxone eligibility checklist; educational handout for patients.</p></list-item><list-item><p>Model: Walk-in.</p></list-item><list-item><p>Roles and processes: (Pharmacist, student pharmacist, technician) Identify naloxone-eligible patients at drop-off. Perform profile search and MME calculations. (Pharmacist) Verify that the patient meets naloxone eligibility. (Pharmacist) Place &#8220;hard stop&#8221; in dispensing software to alert the pharmacist to recommend naloxone. (Pharmacist) Recommend naloxone and provide education on opioid risks and naloxone benefits. Provide educational handout.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Marketing: Not reported.</p></list-item><list-item><p>Formalized policies and procedures: Standardized one-page instruction sheet describing workflow steps posted at each station.</p></list-item><list-item><p>External collaborators: Not reported.</p></list-item><list-item><p>Pricing/reimbursement model: Not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Teeter et al., 2021 [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Statewide standing order.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Communication strategy: Targeted offer (proactive) and general advertisement (passive).</p></list-item><list-item><p>Identification process: (Proactive) Patients flagged in the pharmacy dispensing software if at a high risk of an overdose based on CDC guidelines (&#8805;50 morphine milligram equivalents (MME) per day) or concurrent benzodiazepines, muscle relaxers, or sedative hypnotics. (Passive) Warning sticker on all opioid prescription vial caps dispensed; posters in the pharmacy rotated weekly.</p></list-item><list-item><p>Screening tool: not reported.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Type of service/intervention: OEND.</p></list-item><list-item><p>Intervention details: Naloxone dispensing and education on opioid overdose risk and naloxone using a conversation guide.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Time: Not reported.</p></list-item><list-item><p>Setting: In-person.</p></list-item><list-item><p>Materials: Posters derived from the MOON study [<xref rid="B38-pharmacy-11-00099" ref-type="bibr">38</xref>]; counseling guide with &#8220;conversation starters;&#8221; opioid overdose education pamphlet; naloxone education pamphlet with video training links; generic naloxone demonstration kit.</p></list-item><list-item><p>Model: Walk-in.</p></list-item><list-item><p>Roles and processes: (Pharmacist) Provide opioid overdose education using a pamphlet and conversation guide. (Pharmacist) Recommend naloxone. (Pharmacist) Process naloxone prescription using the patient&#8217;s insurance to determine the cost. (Pharmacist) Dispense naloxone and provide education using a naloxone pamphlet or demonstration kit.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Marketing: Posters in the pharmacy rotated weekly.</p></list-item><list-item><p>Formalized policies and procedures: Not reported.</p></list-item><list-item><p>External collaborators: Not reported.</p></list-item><list-item><p>Pricing/reimbursement model: Study funded by the UAMS Translational Research Institute and National Center of Advancing Translational Sciences. Naloxone product reimbursement via patient insurance.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Santa et al., 2021 [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>]</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Statewide standing order.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Communication strategy: Universal offer.</p></list-item><list-item><p>Identification process: Pharmacy-specific protocols used for recommending naloxone to all patients prescribed opioids (details not reported).</p></list-item><list-item><p>Screening tool: formal screening tool mentioned, but details not reported.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Type of service/intervention: OEND.</p></list-item><list-item><p>Intervention details: Screening, brief intervention, and referral to treatment (SBIRT). Brief intervention included counseling regarding opioid overdose and naloxone using motivational interviewing (MI) and naloxone dispensing.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Time: Not reported.</p></list-item><list-item><p>Setting: In-person.</p></list-item><list-item><p>Materials: SBIRT proficiency checklist; workflow outline using the &#8220;A3&#8221; format.</p></list-item><list-item><p>Model: Not reported.</p></list-item><list-item><p>Roles and processes: (Pharmacist) At least one pharmacist per site served as a program champion. (Champion) Check other pharmacists&#8217; SBIRT abilities using a checklist. (Champion) Monitor naloxone dispensing using a workflow outline each week.</p></list-item></list>
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Marketing: Not reported.</p></list-item><list-item><p>Formalized policies and procedures: Formal naloxone dispensing policies and procedures developed by a pharmacist site champion, specific to each pharmacy (details not reported). Workflow outline for ensuring protocol fidelity.</p></list-item><list-item><p>External collaborators: Not reported.</p></list-item><list-item><p>Pricing/reimbursement model: Study funded by the Pennsylvania Commission on Crime and Delinquency. Patient pricing model not reported.</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Multiple articles describing implementation processes from the same study or a related pilot study (One Rx program). </p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmacy-11-00099-t006" orientation="portrait"><object-id pub-id-type="pii">pharmacy-11-00099-t006_Table 6</object-id><label>Table 6</label><caption><p>Programmatic outcomes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Uptake and Delivery</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Intervention Outcomes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Satisfaction</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Akers et al., 2017 [<xref rid="B10-pharmacy-11-00099" ref-type="bibr">10</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Number of participants reached: Held 27 group events with 5&#8211;350 participants each. Trained 1400 people about naloxone overall.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amount of naloxone recommended/dispensed: Dispensed 234 naloxone kits from the pharmacy. Dispensed 505 naloxone kits via partnership with local county psychologist.</p></list-item><list-item><p>Other OCN program-specific outcomes: 20.2% rescue rate reported from naloxone kits dispensed by the pharmacy.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Patient satisfaction: Anecdotally reported that the program was viewed favorably. No further details reported.</p></list-item><list-item><p>Provider satisfaction: Anecdotally reported that the program was viewed favorably. No further details reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cochran et al., 2019 [<xref rid="B27-pharmacy-11-00099" ref-type="bibr">27</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Number of participants reached: 387 patients identified, 314 screened, 32 consented to participate (BMI-MTM <italic toggle="yes">n</italic> = 15, SMC <italic toggle="yes">n</italic> = 17). A total of 93% retained at 3 months.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amount of naloxone recommended/dispensed: Not reported.</p></list-item><list-item><p>Other OCN program-specific outcomes: After 3 months, the odds of opioid misuse were lower in the BMI-MTM group compared to those in the SMC group (AOR = 0.13; 95% CI = 0.05&#8211;0.35, <italic toggle="yes">p</italic> &lt; 0.001).</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Patient satisfaction: 92.4% of BMI-MTM participants satisfied with the program, with a mean rating of 4.2 out of 5.</p></list-item><list-item><p>Provider satisfaction: Not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Manzur et al., 2020 [<xref rid="B28-pharmacy-11-00099" ref-type="bibr">28</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Number of participants reached: 19 sessions delivered, 11 patients assessed (1&#8211;2 sessions per patient).</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amount of naloxone recommended/dispensed: Naloxone prescribed to 58% of patients.</p></list-item><list-item><p>Other OCN program-specific outcomes: Pharmacists identified opioid/pain medication-related problems most frequently surrounding the need for additional treatment (84%). A total of 74% of recommendations were for additional lab tests, and 58% were related to adjusting the dose of opioid/pain medication.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Patient satisfaction: Not reported.</p></list-item><list-item><p>Provider satisfaction: Not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skoy et al., 2020a [<xref rid="B29-pharmacy-11-00099" ref-type="bibr">29</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Number of participants reached: 1700 patients screened, and 240 pharmacists and 41 technicians trained across 30 pharmacies.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Not reported.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skoy et al., 2020b [<xref rid="B30-pharmacy-11-00099" ref-type="bibr">30</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Number of participants reached: 2716 patients screened; 1371 potentially at risk for opioid overdose or misuse.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amount of naloxone recommended/dispensed: Naloxone recommendations accepted by 5.81% of patients.</p></list-item><list-item><p>Other OCN program-specific outcomes: The naloxone acceptance rate was higher in those with more overdose risk factors (e.g., zero risk factors = 1.18%, five risk factors = 17.09%; <italic toggle="yes">p</italic> &lt; 0.05).</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strand et al., 2020 [<xref rid="B31-pharmacy-11-00099" ref-type="bibr">31</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Number of participants reached: Sixty-three pharmacies enrolled in the program; thirty actively participated. A total of 1685 patients screened.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amount of naloxone recommended/dispensed: Not reported.</p></list-item><list-item><p>Other OCN program-specific outcomes: Reach: patients taking opioid who were screened (16.9%). Efficacy: patients at a high risk of overdose/misuse given intervention (97.1%). Adoption: Pharmacies in North Dakota enrolled in the program (45%). Implementation: Pharmacies that enrolled and participated by conducting five or more screenings (44.8%). Maintenance: Pharmacies that continued participating in the program at 3 months (80%).</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strand et al., 2019 [<xref rid="B34-pharmacy-11-00099" ref-type="bibr">34</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Number of participants reached: 107 patients screened.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amount of naloxone recommended/dispensed: 43 recommended, 5 prescribed, 3 dispensed.</p></list-item><list-item><p>Other OCN program-specific outcomes: 30% and 25% of patients screened were at risk of opioid overdose and misuse, respectively. &#8220;Red flags&#8221; detected in 23% of screenings.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wilkerson et al., 2020 [<xref rid="B19-pharmacy-11-00099" ref-type="bibr">19</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Number of participants reached: 1000 pharmacists and interns across 102 pharmacies.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Not reported.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hines et al., 2020 [<xref rid="B9-pharmacy-11-00099" ref-type="bibr">9</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Number of participants reached: 52 patients enrolled.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amount of naloxone recommended/dispensed: 15 naloxone kits dispensed after intervention; 2 dispensed before intervention. A 400% increase in dispensing.</p></list-item><list-item><p>Other OCN program-specific outcomes: After counseling, more patients believed that they should have naloxone on hand compared to before receiving counseling (40.4% compared to 15.4%, <italic toggle="yes">p</italic> &lt; 0.001).</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sexton et al., 2019 [<xref rid="B32-pharmacy-11-00099" ref-type="bibr">32</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Number of participants reached: 39 patients.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amount of naloxone recommended/dispensed: 11 naloxone kits dispensed by the intervention group during the study period compared to 3 before the study period. A 367% increase in dispensing.</p></list-item><list-item><p>Other OCN program-specific outcomes: Not reported.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Patient satisfaction: Anecdotally reported that two patients used the naloxone dispensed to them and told the pharmacist they were happy they received it.</p></list-item><list-item><p>Provider satisfaction: Not reported.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Teeter et al., 2021 [<xref rid="B14-pharmacy-11-00099" ref-type="bibr">14</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Number of participants reached: 148 patients approached; 130 consented to participate.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amount of naloxone recommended/dispensed: 44 naloxone kits dispensed by the intervention pharmacy; 0 dispensed by control pharmacies.</p></list-item><list-item><p>Other OCN program-specific outcomes: Naloxone dispensed to 15.8% of patients receiving &#8805;50 MME and 36.7% of patients with concomitant medications that increased the risk of opioid overdose.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Patient satisfaction: Not reported.</p></list-item><list-item><p>Provider satisfaction: Upon post-program interviews, pharmacy personnel indicated that the service was feasible, acceptable, and appropriate.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Santa et al., 2021 [<xref rid="B33-pharmacy-11-00099" ref-type="bibr">33</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Number of participants reached: 2082 patients. A total of 24 pharmacists recruited; 22 pharmacists participated.</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Amount of naloxone recommended/dispensed: 1160 naloxone kits recommended; 430 naloxone kits dispensed after the intervention (compared to 180 before the intervention).</p></list-item><list-item><p>Other OCN program-specific outcomes: The amount of naloxone dispensed varied by the pharmacy type (independently owned <italic toggle="yes">n</italic> = 245, corporately owned <italic toggle="yes">n</italic> = 185).</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Not reported.</p></list-item></list>
</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>